{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T01:30:07Z","timestamp":1788485407251,"version":"build-2803163510"},"reference-count":280,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2020,8,24]],"date-time":"2020-08-24T00:00:00Z","timestamp":1598227200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,8,24]],"date-time":"2020-08-24T00:00:00Z","timestamp":1598227200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1007\/s10620-020-06562-2","type":"journal-article","created":{"date-parts":[[2020,8,24]],"date-time":"2020-08-24T07:02:30Z","timestamp":1598252550000},"page":"2493-2512","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Exploring the Pathogenic Role and Therapeutic Implications of Interleukin 2 in Autoimmune Hepatitis"],"prefix":"10.1007","volume":"66","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5024-3065","authenticated-orcid":false,"given":"Albert J.","family":"Czaja","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,8,24]]},"reference":[{"key":"6562_CR1","doi-asserted-by":"publisher","first-page":"2881","DOI":"10.1007\/s10620-015-3708-7","volume":"60","author":"AJ Czaja","year":"2015","unstructured":"Czaja AJ. Transitioning from idiopathic to explainable autoimmune hepatitis. Dig Dis Sci. 2015;60:2881\u20132900. https:\/\/doi.org\/10.1007\/s10620-015-3708-7.","journal-title":"Dig Dis Sci"},{"key":"6562_CR2","doi-asserted-by":"crossref","first-page":"18017","DOI":"10.1038\/nrdp.2018.17","volume":"4","author":"G Mieli-Vergani","year":"2018","unstructured":"Mieli-Vergani G, Vergani D, Czaja AJ, et al. Autoimmune hepatitis. Nat Rev Dis Prim. 2018;4:18017.","journal-title":"Nat Rev Dis Prim"},{"key":"6562_CR3","doi-asserted-by":"crossref","first-page":"6579","DOI":"10.3748\/wjg.v25.i45.6579","volume":"25","author":"AJ Czaja","year":"2019","unstructured":"Czaja AJ. Examining pathogenic concepts of autoimmune hepatitis for cues to future investigations and interventions. World J Gastroenterol. 2019;25:6579\u20136606.","journal-title":"World J Gastroenterol"},{"key":"6562_CR4","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/S0962-8924(00)01856-0","volume":"10","author":"A O\u2019Garra","year":"2000","unstructured":"O\u2019Garra A, Arai N. The molecular basis of T helper 1 and T helper 2 cell differentiation. Trends Cell Biol. 2000;10:542\u2013550.","journal-title":"Trends Cell Biol"},{"key":"6562_CR5","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s12072-010-9183-5","volume":"4","author":"YH Oo","year":"2010","unstructured":"Oo YH, Hubscher SG, Adams DH. Autoimmune hepatitis: new paradigms in the pathogenesis, diagnosis, and management. Hepatol Int. 2010;4:475\u2013493.","journal-title":"Hepatol Int"},{"key":"6562_CR6","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/nri3156","volume":"12","author":"O Boyman","year":"2012","unstructured":"Boyman O, Sprent J. The role of interleukin-2 during homeostasis and activation of the immune system. Nat Rev Immunol. 2012;12:180\u2013190.","journal-title":"Nat Rev Immunol"},{"key":"6562_CR7","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.jaut.2013.06.013","volume":"46","author":"PJ Trivedi","year":"2013","unstructured":"Trivedi PJ, Adams DH. Mucosal immunity in liver autoimmunity: a comprehensive review. J Autoimmun. 2013;46:97\u2013111.","journal-title":"J Autoimmun"},{"key":"6562_CR8","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jaut.2018.10.020","volume":"95","author":"A Floreani","year":"2018","unstructured":"Floreani A, Restrepo-Jimenez P, Secchi MF, et al. Etiopathogenesis of autoimmune hepatitis. J Autoimmun. 2018;95:133\u2013143.","journal-title":"J Autoimmun"},{"key":"6562_CR9","doi-asserted-by":"publisher","DOI":"10.1002\/hep.31065","author":"CL Mack","year":"2019","unstructured":"Mack CL, Adams D, Assis DN, et al. Diagnosis and management of autoimmune hepatitis in adults and children: 2019 practice guidance and guidelines from the American Association for the study of liver diseases. Hepatology. 2019;. https:\/\/doi.org\/10.1002\/hep.31065.","journal-title":"Hepatology"},{"key":"6562_CR10","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1126\/science.1079490","volume":"299","author":"S Hori","year":"2003","unstructured":"Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science. 2003;299:1057\u20131061.","journal-title":"Science"},{"key":"6562_CR11","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1093\/jmcb\/mjr039","volume":"4","author":"Q Lan","year":"2012","unstructured":"Lan Q, Fan H, Quesniaux V, et al. Induced Foxp3(+) regulatory T cells: a potential new weapon to treat autoimmune and inflammatory diseases? J Mol Cell Biol. 2012;4:22\u201328.","journal-title":"J Mol Cell Biol"},{"key":"6562_CR12","doi-asserted-by":"crossref","first-page":"923","DOI":"10.4049\/jimmunol.172.2.923","volume":"172","author":"M Karim","year":"2004","unstructured":"Karim M, Kingsley CI, Bushell AR, Sawitzki BS, Wood KJ. Alloantigen-induced CD25+CD4+ regulatory T cells can develop in vivo from CD25\u2212CD4+ precursors in a thymus-independent process. J Immunol. 2004;172:923\u2013928.","journal-title":"J Immunol"},{"key":"6562_CR13","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.4049\/jimmunol.155.3.1151","volume":"155","author":"S Sakaguchi","year":"1995","unstructured":"Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol. 1995;155:1151\u20131164.","journal-title":"J Immunol"},{"key":"6562_CR14","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1007\/s10620-014-3473-z","volume":"60","author":"AJ Montano-Loza","year":"2014","unstructured":"Montano-Loza AJ, Czaja AJ. Cell mediators of autoimmune hepatitis and their therapeutic implications. Dig Dis Sci. 2014;60:1528\u20131542. https:\/\/doi.org\/10.1007\/s10620-014-3473-z.","journal-title":"Dig Dis Sci"},{"key":"6562_CR15","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1002\/iub.1349","volume":"67","author":"R Liberal","year":"2015","unstructured":"Liberal R, Grant CR, Longhi MS, Mieli-Vergani G, Vergani D. Regulatory T cells: mechanisms of suppression and impairment in autoimmune liver disease. IUBMB Life. 2015;67:88\u201397.","journal-title":"IUBMB Life"},{"key":"6562_CR16","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.autrev.2014.10.012","volume":"14","author":"CR Grant","year":"2015","unstructured":"Grant CR, Liberal R, Mieli-Vergani G, Vergani D, Longhi MS. Regulatory T-cells in autoimmune diseases: challenges, controversies and\u2014yet\u2014unanswered questions. Autoimmun Rev. 2015;14:105\u2013116.","journal-title":"Autoimmun Rev"},{"key":"6562_CR17","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1146\/annurev.immunol.26.021607.090344","volume":"26","author":"C King","year":"2008","unstructured":"King C, Tangye SG, Mackay CR. T follicular helper (TFH) cells in normal and dysregulated immune responses. Annu Rev Immunol. 2008;26:741\u2013766.","journal-title":"Annu Rev Immunol"},{"key":"6562_CR18","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/nature09370","volume":"467","author":"HJ Kim","year":"2010","unstructured":"Kim HJ, Verbinnen B, Tang X, Lu L, Cantor H. Inhibition of follicular T-helper cells by CD8(+) regulatory T cells is essential for self tolerance. Nature. 2010;467:328\u2013332.","journal-title":"Nature"},{"key":"6562_CR19","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1097\/TP.0000000000002258","volume":"102","author":"S Bezie","year":"2018","unstructured":"Bezie S, Anegon I, Guillonneau C. Advances on CD8+ Treg Cells and their potential in transplantation. Transplantation. 2018;102:1467\u20131478.","journal-title":"Transplantation"},{"key":"6562_CR20","doi-asserted-by":"crossref","first-page":"31","DOI":"10.4049\/jimmunol.1701079","volume":"201","author":"KM Valentine","year":"2018","unstructured":"Valentine KM, Davini D, Lawrence TJ, et al. CD8 follicular T cells promote B cell antibody class switch in autoimmune disease. J Immunol. 2018;201:31\u201340.","journal-title":"J Immunol"},{"key":"6562_CR21","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.it.2018.10.002","volume":"39","author":"D Yu","year":"2018","unstructured":"Yu D, Ye L. A portrait of CXCR5(+) follicular cytotoxic CD8(+) T cells. Trends Immunol. 2018;39:965\u2013979.","journal-title":"Trends Immunol"},{"key":"6562_CR22","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.molimm.2020.01.007","volume":"119","author":"G Fousteri","year":"2020","unstructured":"Fousteri G, Kuka M. The elusive identity of CXCR5(+) CD8 T cells in viral infection and autoimmunity: cytotoxic, regulatory, or helper cells? Mol Immunol. 2020;119:101\u2013105.","journal-title":"Mol Immunol"},{"key":"6562_CR23","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1159\/000506806","volume":"181","author":"S Gupta","year":"2020","unstructured":"Gupta S, Agrawal S. In vitro effects of CD8+ regulatory T cells on human B cell subpopulations. Int Arch Allergy Immunol. 2020;181:476\u2013480.","journal-title":"Int Arch Allergy Immunol"},{"key":"6562_CR24","doi-asserted-by":"crossref","first-page":"3983","DOI":"10.4049\/jimmunol.172.7.3983","volume":"172","author":"BH Nelson","year":"2004","unstructured":"Nelson BH. IL-2, regulatory T cells, and tolerance. J Immunol. 2004;172:3983\u20133988.","journal-title":"J Immunol"},{"key":"6562_CR25","doi-asserted-by":"crossref","first-page":"3105","DOI":"10.4049\/jimmunol.165.6.3105","volume":"165","author":"LA Stephens","year":"2000","unstructured":"Stephens LA, Mason D. CD25 is a marker for CD4+ thymocytes that prevent autoimmune diabetes in rats, but peripheral T cells with this function are found in both CD25+ and CD25\u2212 subpopulations. J Immunol. 2000;165:3105\u20133110.","journal-title":"J Immunol"},{"key":"6562_CR26","doi-asserted-by":"crossref","first-page":"5558","DOI":"10.4049\/jimmunol.168.11.5558","volume":"168","author":"L Graca","year":"2002","unstructured":"Graca L, Thompson S, Lin CY, et al. Both CD4(+)CD25(+) and CD4(+)CD25(\u2212) regulatory cells mediate dominant transplantation tolerance. J Immunol. 2002;168:5558\u20135565.","journal-title":"J Immunol"},{"key":"6562_CR27","doi-asserted-by":"crossref","first-page":"6323","DOI":"10.4049\/jimmunol.171.12.6323","volume":"171","author":"H Jonuleit","year":"2003","unstructured":"Jonuleit H, Schmitt E. The regulatory T cell family: distinct subsets and their interrelations. J Immunol. 2003;171:6323\u20136327.","journal-title":"J Immunol"},{"key":"6562_CR28","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/nri1026","volume":"3","author":"JF Bach","year":"2003","unstructured":"Bach JF. Regulatory T cells under scrutiny. Nat Rev Immunol. 2003;3:189\u2013198.","journal-title":"Nat Rev Immunol"},{"key":"6562_CR29","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/j.jhep.2013.05.034","volume":"59","author":"YH Oo","year":"2013","unstructured":"Oo YH, Sakaguchi S. Regulatory T-cell directed therapies in liver diseases. J Hepatol. 2013;59:1127\u20131134.","journal-title":"J Hepatol"},{"key":"6562_CR30","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1586\/17474124.2015.1019470","volume":"9","author":"AJ Czaja","year":"2015","unstructured":"Czaja AJ. Adoptive cell transfer in autoimmune hepatitis. Expert Rev Gastroenterol Hepatol. 2015;9:821\u2013836.","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"6562_CR31","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.jhep.2015.06.030","volume":"63","author":"EASL Clinical Practice Guidelines","year":"2015","unstructured":"EASL Clinical Practice Guidelines. Autoimmune hepatitis. J Hepatol. 2015;63:971\u20131004.","journal-title":"J Hepatol"},{"key":"6562_CR32","doi-asserted-by":"crossref","unstructured":"Czaja AJ. Review article: opportunities to improve and expand thiopurine therapy for autoimmune hepatitis. Aliment Pharmacol Ther. 2020;51:1286\u20131304.","DOI":"10.1111\/apt.15743"},{"key":"6562_CR33","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1210\/en.2012-2045","volume":"154","author":"S Vandevyver","year":"2013","unstructured":"Vandevyver S, Dejager L, Tuckermann J, Libert C. New insights into the anti-inflammatory mechanisms of glucocorticoids: an emerging role for glucocorticoid-receptor-mediated transactivation. Endocrinology. 2013;154:993\u20131007.","journal-title":"Endocrinology"},{"key":"6562_CR34","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1210\/er.2002-0006","volume":"24","author":"K De Bosscher","year":"2003","unstructured":"De Bosscher K, Vanden Berghe W, Haegeman G. The interplay between the glucocorticoid receptor and nuclear factor-kappaB or activator protein-1: molecular mechanisms for gene repression. Endocr Rev. 2003;24:488\u2013522.","journal-title":"Endocr Rev"},{"key":"6562_CR35","first-page":"435","volume":"20","author":"LI McKay","year":"1999","unstructured":"McKay LI, Cidlowski JA. Molecular control of immune\/inflammatory responses: interactions between nuclear factor-kappa B and steroid receptor-signaling pathways. Endocr Rev. 1999;20:435\u2013459.","journal-title":"Endocr Rev"},{"key":"6562_CR36","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.molmed.2007.02.001","volume":"13","author":"M Lowenberg","year":"2007","unstructured":"Lowenberg M, Verhaar AP, van den Brink GR, Hommes DW. Glucocorticoid signaling: a nongenomic mechanism for T-cell immunosuppression. Trends Mol Med. 2007;13:158\u2013163.","journal-title":"Trends Mol Med"},{"key":"6562_CR37","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1124\/jpet.104.074815","volume":"312","author":"CW Thomas","year":"2005","unstructured":"Thomas CW, Myhre GM, Tschumper R, et al. Selective inhibition of inflammatory gene expression in activated T lymphocytes: a mechanism of immune suppression by thiopurines. J Pharmacol Exp Ther. 2005;312:537\u2013545.","journal-title":"J Pharmacol Exp Ther"},{"key":"6562_CR38","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1586\/egh.12.40","volume":"6","author":"AJ Czaja","year":"2012","unstructured":"Czaja AJ. Drug choices in autoimmune hepatitis: part A\u2014steroids. Expert Rev Gastroenterol Hepatol. 2012;6:603\u2013615.","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"6562_CR39","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1586\/egh.12.38","volume":"6","author":"AJ Czaja","year":"2012","unstructured":"Czaja AJ. Drug choices in autoimmune hepatitis: part B\u2014nonsteroids. Expert Rev Gastroenterol Hepatol. 2012;6:617\u2013635.","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"6562_CR40","doi-asserted-by":"crossref","first-page":"4360","DOI":"10.4049\/jimmunol.1201520","volume":"190","author":"N Muller","year":"2013","unstructured":"Muller N, Fischer HJ, Tischner D, van den Brandt J, Reichardt HM. Glucocorticoids induce effector T cell depolarization via ERM proteins, thereby impeding migration and APC conjugation. J Immunol. 2013;190:4360\u20134370.","journal-title":"J Immunol"},{"key":"6562_CR41","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1016\/j.jaci.2004.07.014","volume":"114","author":"C Karagiannidis","year":"2004","unstructured":"Karagiannidis C, Akdis M, Holopainen P, et al. Glucocorticoids upregulate FOXP3 expression and regulatory T cells in asthma. J Allergy Clin Immunol. 2004;114:1425\u20131433.","journal-title":"J Allergy Clin Immunol"},{"key":"6562_CR42","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1080\/10408360590888983","volume":"42","author":"JP Tuckermann","year":"2005","unstructured":"Tuckermann JP, Kleiman A, McPherson KG, Reichardt HM. Molecular mechanisms of glucocorticoids in the control of inflammation and lymphocyte apoptosis. Crit Rev Clin Lab Sci. 2005;42:71\u2013104.","journal-title":"Crit Rev Clin Lab Sci"},{"key":"6562_CR43","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1136\/ard.2005.049924","volume":"65","author":"A Suarez","year":"2006","unstructured":"Suarez A, Lopez P, Gomez J, Gutierrez C. Enrichment of CD4+CD25high T cell population in patients with systemic lupus erythematosus treated with glucocorticoids. Ann Rheum Dis. 2006;65:1512\u20131517.","journal-title":"Ann Rheum Dis"},{"key":"6562_CR44","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.celrep.2014.03.004","volume":"7","author":"O Bereshchenko","year":"2014","unstructured":"Bereshchenko O, Coppo M, Bruscoli S, et al. GILZ promotes production of peripherally induced Treg cells and mediates the crosstalk between glucocorticoids and TGF-beta signaling. Cell Rep. 2014;7:464\u2013475.","journal-title":"Cell Rep"},{"key":"6562_CR45","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1097\/TP.0000000000001379","volume":"100","author":"A Furukawa","year":"2016","unstructured":"Furukawa A, Wisel SA, Tang Q. Impact of immune-modulatory drugs on regulatory T cells. Transplantation. 2016;100:2288\u20132300.","journal-title":"Transplantation"},{"key":"6562_CR46","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/S2468-1253(18)30043-8","volume":"3","author":"D Jones","year":"2018","unstructured":"Jones D, Manns MP, Terracciano L, Torbenson M, Vierling JM. Unmet needs and new models for future trials in autoimmune hepatitis. Lancet Gastroenterol Hepatol. 2018;3:363\u2013370.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"6562_CR47","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/nri1435","volume":"4","author":"TR Malek","year":"2004","unstructured":"Malek TR, Bayer AL. Tolerance, not immunity, crucially depends on IL-2. Nat Rev Immunol. 2004;4:665\u2013674.","journal-title":"Nat Rev Immunol"},{"key":"6562_CR48","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/0008-8749(85)90338-7","volume":"96","author":"JH Kehrl","year":"1985","unstructured":"Kehrl JH, Muraguchi A, Goldsmith PK, Fauci AS. The direct effects of interleukin 1, interleukin 2, interferon-alpha, interferon-gamma, B-cell growth factor, and a B-cell differentiation factor on resting and activated human B cells. Cell Immunol. 1985;96:38\u201348.","journal-title":"Cell Immunol"},{"key":"6562_CR49","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/BF00915548","volume":"7","author":"T Miyawaki","year":"1987","unstructured":"Miyawaki T, Suzuki T, Butler JL, Cooper MD. Interleukin-2 effects on human B cells activated in vivo. J Clin Immunol. 1987;7:277\u2013287.","journal-title":"J Clin Immunol"},{"key":"6562_CR50","doi-asserted-by":"crossref","first-page":"465","DOI":"10.4049\/jimmunol.140.2.465","volume":"140","author":"T Nakagawa","year":"1988","unstructured":"Nakagawa T, Nakagawa N, Ambrus JL Jr, Fauci AS. Differential effects of interleukin 2 versus B cell growth factor on human B cells. J Immunol. 1988;140:465\u2013469.","journal-title":"J Immunol"},{"key":"6562_CR51","first-page":"322","volume":"73","author":"A Franz","year":"1991","unstructured":"Franz A, Bryant A, Farrant J. Interleukin-2-induced DNA synthesis and immunoglobulin secretion by resting human tonsillar B cells: effects of protein kinase C activation. Immunology. 1991;73:322\u2013326.","journal-title":"Immunology"},{"key":"6562_CR52","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1006\/cimm.1994.1235","volume":"157","author":"W Stohl","year":"1994","unstructured":"Stohl W, Elliott JE, Wang H, Lin YG, Horwitz DA. Enhancing effects of interleukin 2-treated peripheral blood mononuclear cells on subsequent B cell differentiation. Cell Immunol. 1994;157:381\u2013392.","journal-title":"Cell Immunol"},{"key":"6562_CR53","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1128\/cdli.1.4.424-432.1994","volume":"1","author":"CL Patke","year":"1994","unstructured":"Patke CL, Green CG, Shearer WT. Differential effects of interleukin-2 and interleukin-4 on immunomodulatory role of platelet-activating factor in human B cells. Clin Diagn Lab Immunol. 1994;1:424\u2013432.","journal-title":"Clin Diagn Lab Immunol"},{"key":"6562_CR54","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0065-2776(04)86006-1","volume":"86","author":"B Becknell","year":"2005","unstructured":"Becknell B, Caligiuri MA. Interleukin-2, interleukin-15, and their roles in human natural killer cells. Adv Immunol. 2005;86:209\u2013239.","journal-title":"Adv Immunol"},{"key":"6562_CR55","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.it.2015.10.003","volume":"36","author":"N Arenas-Ramirez","year":"2015","unstructured":"Arenas-Ramirez N, Woytschak J, Boyman O. Interleukin-2: biology, design and application. Trends Immunol. 2015;36:763\u2013777.","journal-title":"Trends Immunol"},{"key":"6562_CR56","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/j.jaci.2016.06.033","volume":"138","author":"M Akdis","year":"2016","unstructured":"Akdis M, Aab A, Altunbulakli C, et al. Interleukins (from IL-1 to IL-38), interferons, transforming growth factor beta, and TNF-alpha: receptors, functions, and roles in diseases. J Allergy Clin Immunol. 2016;138:984\u20131010.","journal-title":"J Allergy Clin Immunol"},{"key":"6562_CR57","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/j.1600-065X.1980.tb00327.x","volume":"51","author":"KA Smith","year":"1980","unstructured":"Smith KA. T-cell growth factor. Immunol Rev. 1980;51:337\u2013357.","journal-title":"Immunol Rev"},{"key":"6562_CR58","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1126\/science.3131876","volume":"240","author":"KA Smith","year":"1988","unstructured":"Smith KA. Interleukin-2: inception, impact, and implications. Science. 1988;240:1169\u20131176.","journal-title":"Science"},{"key":"6562_CR59","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S1074-7613(02)00367-9","volume":"17","author":"TR Malek","year":"2002","unstructured":"Malek TR, Yu A, Vincek V, Scibelli P, Kong L. CD4 regulatory T cells prevent lethal autoimmunity in IL-2Rbeta-deficient mice. Implications for the nonredundant function of IL-2. Immunity. 2002;17:167\u2013178.","journal-title":"Immunity"},{"key":"6562_CR60","doi-asserted-by":"crossref","first-page":"5287","DOI":"10.4049\/jimmunol.172.9.5287","volume":"172","author":"SJ Bensinger","year":"2004","unstructured":"Bensinger SJ, Walsh PT, Zhang J, et al. Distinct IL-2 receptor signaling pattern in CD4+CD25+ regulatory T cells. J Immunol. 2004;172:5287\u20135296.","journal-title":"J Immunol"},{"key":"6562_CR61","doi-asserted-by":"crossref","first-page":"6519","DOI":"10.4049\/jimmunol.172.11.6519","volume":"172","author":"AM Thornton","year":"2004","unstructured":"Thornton AM, Donovan EE, Piccirillo CA, Shevach EM. Cutting edge: IL-2 is critically required for the in vitro activation of CD4+CD25+ T cell suppressor function. J Immunol. 2004;172:6519\u20136523.","journal-title":"J Immunol"},{"key":"6562_CR62","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1002\/eji.200324455","volume":"34","author":"AM Thornton","year":"2004","unstructured":"Thornton AM, Piccirillo CA, Shevach EM. Activation requirements for the induction of CD4+CD25+ T cell suppressor function. Eur J Immunol. 2004;34:366\u2013376.","journal-title":"Eur J Immunol"},{"key":"6562_CR63","doi-asserted-by":"publisher","unstructured":"Abbas AK, Trotta E, Simeonov DR, Marson A, Bluestone JA. Revisiting IL-2: biology and therapeutic prospects. Sci Immunol. 2018. https:\/\/doi.org\/10.1126\/sciimmunol.aat1482.","DOI":"10.1126\/sciimmunol.aat1482"},{"key":"6562_CR64","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1093\/intimm\/4.6.661","volume":"4","author":"B Beverly","year":"1992","unstructured":"Beverly B, Kang SM, Lenardo MJ, Schwartz RH. Reversal of in vitro T cell clonal anergy by IL-2 stimulation. Int Immunol. 1992;4:661\u2013671.","journal-title":"Int Immunol"},{"key":"6562_CR65","first-page":"96","volume":"4","author":"MV Doyle","year":"1985","unstructured":"Doyle MV, Lee MT, Fong S. Comparison of the biological activities of human recombinant interleukin-2(125) and native interleukin-2. J Biol Response Mod. 1985;4:96\u2013109.","journal-title":"J Biol Response Mod"},{"key":"6562_CR66","first-page":"1834","volume":"46","author":"WJ Black","year":"1989","unstructured":"Black WJ. Drug products of recombinant DNA technology. Am J Hosp Pharm. 1989;46:1834\u20131844.","journal-title":"Am J Hosp Pharm"},{"key":"6562_CR67","doi-asserted-by":"crossref","first-page":"394","DOI":"10.2165\/00063030-199707050-00007","volume":"7","author":"S Noble","year":"1997","unstructured":"Noble S, Goa KL. Aldesleukin (recombinant interleukin-2). Biodrugs. 1997;7:394\u2013422.","journal-title":"Biodrugs"},{"key":"6562_CR68","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/s41586-018-0830-7","volume":"565","author":"DA Silva","year":"2019","unstructured":"Silva DA, Yu S, Ulge UY, et al. De novo design of potent and selective mimics of IL-2 and IL-15. Nature. 2019;565:186\u2013191.","journal-title":"Nature"},{"key":"6562_CR69","doi-asserted-by":"crossref","first-page":"e005559","DOI":"10.1136\/bmjopen-2014-005559","volume":"4","author":"F Waldron-Lynch","year":"2014","unstructured":"Waldron-Lynch F, Kareclas P, Irons K, et al. Rationale and study design of the adaptive study of IL-2 dose on regulatory T cells in type 1 diabetes (DILT1D): a non-randomised, open label, adaptive dose finding trial. BMJ Open. 2014;4:e005559.","journal-title":"BMJ Open"},{"key":"6562_CR70","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1056\/NEJMoa1105143","volume":"365","author":"D Saadoun","year":"2011","unstructured":"Saadoun D, Rosenzwajg M, Joly F, et al. Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis. N Engl J Med. 2011;365:2067\u20132077.","journal-title":"N Engl J Med"},{"key":"6562_CR71","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1056\/NEJMoa1108188","volume":"365","author":"J Koreth","year":"2011","unstructured":"Koreth J, Matsuoka K, Kim HT, et al. Interleukin-2 and regulatory T cells in graft-versus-host disease. N Engl J Med. 2011;365:2055\u20132066.","journal-title":"N Engl J Med"},{"key":"6562_CR72","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S2213-8587(13)70113-X","volume":"1","author":"A Hartemann","year":"2013","unstructured":"Hartemann A, Bensimon G, Payan CA, et al. Low-dose interleukin 2 in patients with type 1 diabetes: a phase 1\/2 randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2013;1:295\u2013305.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"6562_CR73","doi-asserted-by":"crossref","first-page":"179ra143","DOI":"10.1126\/scitranslmed.3005265","volume":"5","author":"K Matsuoka","year":"2013","unstructured":"Matsuoka K, Koreth J, Kim HT, et al. Low-dose interleukin-2 therapy restores regulatory T cell homeostasis in patients with chronic graft-versus-host disease. Sci Transl Med. 2013;5:179ra143.","journal-title":"Sci Transl Med"},{"key":"6562_CR74","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1001\/jamadermatol.2014.504","volume":"150","author":"E Castela","year":"2014","unstructured":"Castela E, Le Duff F, Butori C, et al. Effects of low-dose recombinant interleukin 2 to promote T-regulatory cells in alopecia areata. JAMA Dermatol. 2014;150:748\u2013751.","journal-title":"JAMA Dermatol"},{"key":"6562_CR75","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jaut.2015.01.001","volume":"58","author":"M Rosenzwajg","year":"2015","unstructured":"Rosenzwajg M, Churlaud G, Mallone R, et al. Low-dose interleukin-2 fosters a dose-dependent regulatory T cell tuned milieu in T1D patients. J Autoimmun. 2015;58:48\u201358.","journal-title":"J Autoimmun"},{"key":"6562_CR76","first-page":"651","volume":"6","author":"MN Pham","year":"2015","unstructured":"Pham MN, von Herrath MG, Vela JL. Antigen-specific regulatory T cells and low dose of IL-2 in treatment of type 1 diabetes. Front Immunol. 2015;6:651.","journal-title":"Front Immunol"},{"key":"6562_CR77","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1136\/annrheumdis-2015-207776","volume":"75","author":"C von Spee-Mayer","year":"2016","unstructured":"von Spee-Mayer C, Siegert E, Abdirama D, et al. Low-dose interleukin-2 selectively corrects regulatory T cell defects in patients with systemic lupus erythematosus. Ann Rheum Dis. 2016;75:1407\u20131415.","journal-title":"Ann Rheum Dis"},{"key":"6562_CR78","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/nm.4148","volume":"22","author":"J He","year":"2016","unstructured":"He J, Zhang X, Wei Y, et al. Low-dose interleukin-2 treatment selectively modulates CD4(+) T cell subsets in patients with systemic lupus erythematosus. Nat Med. 2016;22:991\u2013993.","journal-title":"Nat Med"},{"key":"6562_CR79","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1136\/annrheumdis-2018-214229","volume":"78","author":"M Rosenzwajg","year":"2019","unstructured":"Rosenzwajg M, Lorenzon R, Cacoub P, et al. Immunological and clinical effects of low-dose interleukin-2 across 11 autoimmune diseases in a single, open clinical trial. Ann Rheum Dis. 2019;78:209\u2013217.","journal-title":"Ann Rheum Dis"},{"key":"6562_CR80","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1002\/hep.30059","volume":"68","author":"TY Lim","year":"2018","unstructured":"Lim TY, Martinez-Llordella M, Kodela E, et al. Low-dose interleukin-2 for refractory autoimmune hepatitis. Hepatology. 2018;68:1649\u20131652.","journal-title":"Hepatology"},{"key":"6562_CR81","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.cyto.2019.01.007","volume":"116","author":"PA Reche","year":"2019","unstructured":"Reche PA. The tertiary structure of \u03b3c cytokines dictates receptor sharing. Cytokine. 2019;116:161\u2013168.","journal-title":"Cytokine"},{"key":"6562_CR82","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0969-2126(00)00018-6","volume":"2","author":"DA Rozwarski","year":"1994","unstructured":"Rozwarski DA, Gronenborn AM, Clore GM, et al. Structural comparisons among the short-chain helical cytokines. Structure. 1994;2:159\u2013173.","journal-title":"Structure"},{"key":"6562_CR83","doi-asserted-by":"crossref","first-page":"3926","DOI":"10.4049\/jimmunol.1800097","volume":"200","author":"DL Owen","year":"2018","unstructured":"Owen DL, Mahmud SA, Vang KB, et al. Identification of cellular sources of IL-2 needed for regulatory T cell development and homeostasis. J Immunol. 2018;200:3926\u20133933.","journal-title":"J Immunol"},{"key":"6562_CR84","doi-asserted-by":"crossref","first-page":"5945","DOI":"10.4049\/jimmunol.166.10.5945","volume":"166","author":"H Bassiri","year":"2001","unstructured":"Bassiri H, Carding SR. A requirement for IL-2\/IL-2 receptor signaling in intrathymic negative selection. J Immunol. 2001;166:5945\u20135954.","journal-title":"J Immunol"},{"key":"6562_CR85","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1155\/1998\/12421","volume":"5","author":"JA Yang-Snyder","year":"1998","unstructured":"Yang-Snyder JA, Rothenberg EV. Spontaneous expression of interleukin-2 in vivo in specific tissues of young mice. Dev Immunol. 1998;5:223\u2013245.","journal-title":"Dev Immunol"},{"key":"6562_CR86","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.immuni.2009.01.006","volume":"30","author":"W Wojciechowski","year":"2009","unstructured":"Wojciechowski W, Harris DP, Sprague F, et al. Cytokine-producing effector B cells regulate type 2 immunity to H. polygyrus. Immunity. 2009;30:421\u2013433.","journal-title":"Immunity"},{"key":"6562_CR87","doi-asserted-by":"crossref","first-page":"3793","DOI":"10.4049\/jimmunol.163.7.3793","volume":"163","author":"LE Wrenshall","year":"1999","unstructured":"Wrenshall LE, Platt JL. Regulation of T cell homeostasis by heparan sulfate-bound IL-2. J Immunol. 1999;163:3793\u20133800.","journal-title":"J Immunol"},{"key":"6562_CR88","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1038\/ni0901-882","volume":"2","author":"F Granucci","year":"2001","unstructured":"Granucci F, Vizzardelli C, Pavelka N, et al. Inducible IL-2 production by dendritic cells revealed by global gene expression analysis. Nat Immunol. 2001;2:882\u2013888.","journal-title":"Nat Immunol"},{"key":"6562_CR89","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1084\/jem.20040370","volume":"200","author":"F Granucci","year":"2004","unstructured":"Granucci F, Zanoni I, Pavelka N, et al. A contribution of mouse dendritic cell-derived IL-2 for NK cell activation. J Exp Med. 2004;200:287\u2013295.","journal-title":"J Exp Med"},{"key":"6562_CR90","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/ni.3171","volume":"16","author":"BM Weist","year":"2015","unstructured":"Weist BM, Kurd N, Boussier J, Chan SW, Robey EA. Thymic regulatory T cell niche size is dictated by limiting IL-2 from antigen-bearing dendritic cells and feedback competition. Nat Immunol. 2015;16:635\u2013641.","journal-title":"Nat Immunol"},{"key":"6562_CR91","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1093\/intimm\/10.4.371","volume":"10","author":"M Papiernik","year":"1998","unstructured":"Papiernik M, de Moraes ML, Pontoux C, Vasseur F, Penit C. Regulatory CD4 T cells: expression of IL-2R alpha chain, resistance to clonal deletion and IL-2 dependency. Int Immunol. 1998;10:371\u2013378.","journal-title":"Int Immunol"},{"key":"6562_CR92","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1034\/j.1600-065X.2001.1820104.x","volume":"182","author":"EM Shevach","year":"2001","unstructured":"Shevach EM, McHugh RS, Piccirillo CA, Thornton AM. Control of T-cell activation by CD4+ CD25+ suppressor T cells. Immunol Rev. 2001;182:58\u201367.","journal-title":"Immunol Rev"},{"key":"6562_CR93","doi-asserted-by":"crossref","first-page":"2707","DOI":"10.1084\/jem.20122759","volume":"210","author":"IF Amado","year":"2013","unstructured":"Amado IF, Berges J, Luther RJ, et al. IL-2 coordinates IL-2-producing and regulatory T cell interplay. J Exp Med. 2013;210:2707\u20132720.","journal-title":"J Exp Med"},{"key":"6562_CR94","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0065-2776(08)60386-7","volume":"70","author":"BH Nelson","year":"1998","unstructured":"Nelson BH, Willerford DM. Biology of the interleukin-2 receptor. Adv Immunol. 1998;70:1\u201381.","journal-title":"Adv Immunol"},{"key":"6562_CR95","doi-asserted-by":"crossref","first-page":"3527","DOI":"10.4049\/jimmunol.164.7.3527","volume":"164","author":"DT Leung","year":"2000","unstructured":"Leung DT, Morefield S, Willerford DM. Regulation of lymphoid homeostasis by IL-2 receptor signals in vivo. J Immunol. 2000;164:3527\u20133534.","journal-title":"J Immunol"},{"key":"6562_CR96","doi-asserted-by":"crossref","first-page":"4754","DOI":"10.1093\/emboj\/18.17.4754","volume":"18","author":"T Nosaka","year":"1999","unstructured":"Nosaka T, Kawashima T, Misawa K, et al. STAT5 as a molecular regulator of proliferation, differentiation and apoptosis in hematopoietic cells. EMBO J. 1999;18:4754\u20134765.","journal-title":"EMBO J"},{"key":"6562_CR97","doi-asserted-by":"crossref","first-page":"5042","DOI":"10.4049\/jimmunol.171.10.5042","volume":"171","author":"JW Snow","year":"2003","unstructured":"Snow JW, Abraham N, Ma MC, et al. Loss of tolerance and autoimmunity affecting multiple organs in STAT5A\/5B-deficient mice. J Immunol. 2003;171:5042\u20135050.","journal-title":"J Immunol"},{"key":"6562_CR98","doi-asserted-by":"crossref","first-page":"3435","DOI":"10.4049\/jimmunol.171.7.3435","volume":"171","author":"A Antov","year":"2003","unstructured":"Antov A, Yang L, Vig M, Baltimore D, Van Parijs L. Essential role for STAT5 signaling in CD25+CD4+ regulatory T cell homeostasis and the maintenance of self-tolerance. J Immunol. 2003;171:3435\u20133441.","journal-title":"J Immunol"},{"key":"6562_CR99","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/j.cell.2014.07.031","volume":"158","author":"Y Feng","year":"2014","unstructured":"Feng Y, Arvey A, Chinen T, et al. Control of the inheritance of regulatory T cell identity by a cis element in the Foxp3 locus. Cell. 2014;158:749\u2013763.","journal-title":"Cell"},{"key":"6562_CR100","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1038\/ni.3540","volume":"17","author":"T Chinen","year":"2016","unstructured":"Chinen T, Kannan AK, Levine AG, et al. An essential role for the IL-2 receptor in Treg cell function. Nat Immunol. 2016;17:1322\u20131333.","journal-title":"Nat Immunol"},{"key":"6562_CR101","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1007\/s002510050250","volume":"46","author":"J Eskdale","year":"1997","unstructured":"Eskdale J, Kube D, Tesch H, Gallagher G. Mapping of the human IL10 gene and further characterization of the 5\u2032 flanking sequence. Immunogenetics. 1997;46:120\u2013128.","journal-title":"Immunogenetics"},{"key":"6562_CR102","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1146\/annurev.immunol.19.1.683","volume":"19","author":"KW Moore","year":"2001","unstructured":"Moore KW, de Waal Malefyt R, Coffman RL, O\u2019Garra A. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol. 2001;19:683\u2013765.","journal-title":"Annu Rev Immunol"},{"key":"6562_CR103","doi-asserted-by":"crossref","first-page":"6427","DOI":"10.4049\/jimmunol.172.10.6427","volume":"172","author":"A Skapenko","year":"2004","unstructured":"Skapenko A, Niedobitek GU, Kalden JR, Lipsky PE, Schulze-Koops H. Generation and regulation of human Th1-biased immune responses in vivo: a critical role for IL-4 and IL-10. J Immunol. 2004;172:6427\u20136434.","journal-title":"J Immunol"},{"key":"6562_CR104","doi-asserted-by":"crossref","first-page":"3897","DOI":"10.4049\/jimmunol.181.6.3897","volume":"181","author":"K Tsuji-Takayama","year":"2008","unstructured":"Tsuji-Takayama K, Suzuki M, Yamamoto M, et al. The production of IL-10 by human regulatory T cells is enhanced by IL-2 through a STAT5-responsive intronic enhancer in the IL-10 locus. J Immunol. 2008;181:3897\u20133905.","journal-title":"J Immunol"},{"key":"6562_CR105","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/nri2711","volume":"10","author":"M Saraiva","year":"2010","unstructured":"Saraiva M, O\u2019Garra A. The regulation of IL-10 production by immune cells. Nat Rev Immunol. 2010;10:170\u2013181.","journal-title":"Nat Rev Immunol"},{"key":"6562_CR106","doi-asserted-by":"crossref","first-page":"3880","DOI":"10.1073\/pnas.0400339101","volume":"101","author":"J Cote-Sierra","year":"2004","unstructured":"Cote-Sierra J, Foucras G, Guo L, et al. Interleukin 2 plays a central role in Th2 differentiation. Proc Natl Acad Sci U S A. 2004;101:3880\u20133885.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"6562_CR107","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1084\/jem.176.4.1091","volume":"176","author":"RA Seder","year":"1992","unstructured":"Seder RA, Paul WE, Davis MM, Fazekas de St Groth B. The presence of interleukin 4 during in vitro priming determines the lymphokine-producing potential of CD4+ T cells from T cell receptor transgenic mice. J Exp Med. 1992;176:1091\u20131098.","journal-title":"J Exp Med"},{"key":"6562_CR108","doi-asserted-by":"crossref","first-page":"6065","DOI":"10.1073\/pnas.89.13.6065","volume":"89","author":"CS Hsieh","year":"1992","unstructured":"Hsieh CS, Heimberger AB, Gold JS, O\u2019Garra A, Murphy KM. Differential regulation of T helper phenotype development by interleukins 4 and 10 in an alpha beta T-cell-receptor transgenic system. Proc Natl Acad Sci U S A. 1992;89:6065\u20136069.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"6562_CR109","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/S1074-7613(00)80671-8","volume":"9","author":"W Ouyang","year":"1998","unstructured":"Ouyang W, Ranganath SH, Weindel K, et al. Inhibition of Th1 development mediated by GATA-3 through an IL-4-independent mechanism. Immunity. 1998;9:745\u2013755.","journal-title":"Immunity"},{"key":"6562_CR110","doi-asserted-by":"crossref","first-page":"6107","DOI":"10.4049\/jimmunol.175.9.6107","volume":"175","author":"A Skapenko","year":"2005","unstructured":"Skapenko A, Kalden JR, Lipsky PE, Schulze-Koops H. The IL-4 receptor alpha-chain-binding cytokines, IL-4 and IL-13, induce forkhead box P3-expressing CD25+CD4+ regulatory T cells from CD25\u2212CD4+ precursors. J Immunol. 2005;175:6107\u20136116.","journal-title":"J Immunol"},{"key":"6562_CR111","doi-asserted-by":"crossref","first-page":"2905","DOI":"10.4049\/jimmunol.164.6.2905","volume":"164","author":"TR Malek","year":"2000","unstructured":"Malek TR, Porter BO, Codias EK, Scibelli P, Yu A. Normal lymphoid homeostasis and lack of lethal autoimmunity in mice containing mature T cells with severely impaired IL-2 receptors. J Immunol. 2000;164:2905\u20132914.","journal-title":"J Immunol"},{"key":"6562_CR112","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1038\/352621a0","volume":"352","author":"H Schorle","year":"1991","unstructured":"Schorle H, Holtschke T, Hunig T, Schimpl A, Horak I. Development and function of T cells in mice rendered interleukin-2 deficient by gene targeting. Nature. 1991;352:621\u2013624.","journal-title":"Nature"},{"key":"6562_CR113","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/0092-8674(93)80067-O","volume":"75","author":"B Sadlack","year":"1993","unstructured":"Sadlack B, Merz H, Schorle H, et al. Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene. Cell. 1993;75:253\u2013261.","journal-title":"Cell"},{"key":"6562_CR114","doi-asserted-by":"crossref","first-page":"3053","DOI":"10.1002\/eji.1830251111","volume":"25","author":"B Sadlack","year":"1995","unstructured":"Sadlack B, Lohler J, Schorle H, et al. Generalized autoimmune disease in interleukin-2-deficient mice is triggered by an uncontrolled activation and proliferation of CD4+ T cells. Eur J Immunol. 1995;25:3053\u20133059.","journal-title":"Eur J Immunol"},{"key":"6562_CR115","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/1074-7613(95)90180-9","volume":"3","author":"DM Willerford","year":"1995","unstructured":"Willerford DM, Chen J, Ferry JA, et al. Interleukin-2 receptor alpha chain regulates the size and content of the peripheral lymphoid compartment. Immunity. 1995;3:521\u2013530.","journal-title":"Immunity"},{"key":"6562_CR116","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1002\/eji.1830240144","volume":"24","author":"B Sadlack","year":"1994","unstructured":"Sadlack B, Kuhn R, Schorle H, et al. Development and proliferation of lymphocytes in mice deficient for both interleukins-2 and -4. Eur J Immunol. 1994;24:281\u2013284.","journal-title":"Eur J Immunol"},{"key":"6562_CR117","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1126\/science.8235625","volume":"262","author":"TM Kundig","year":"1993","unstructured":"Kundig TM, Schorle H, Bachmann MF, et al. Immune responses in interleukin-2-deficient mice. Science. 1993;262:1059\u20131061.","journal-title":"Science"},{"key":"6562_CR118","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1002\/eji.1830241009","volume":"24","author":"S Kramer","year":"1994","unstructured":"Kramer S, Mamalaki C, Horak I, et al. Thymic selection and peptide-induced activation of T cell receptor-transgenic CD8 T cells in interleukin-2-deficient mice. Eur J Immunol. 1994;24:2317\u20132322.","journal-title":"Eur J Immunol"},{"key":"6562_CR119","doi-asserted-by":"crossref","first-page":"4850","DOI":"10.4049\/jimmunol.169.9.4850","volume":"169","author":"AR Almeida","year":"2002","unstructured":"Almeida AR, Legrand N, Papiernik M, Freitas AA. Homeostasis of peripheral CD4+ T cells: IL-2R alpha and IL-2 shape a population of regulatory cells that controls CD4+ T cell numbers. J Immunol. 2002;169:4850\u20134860.","journal-title":"J Immunol"},{"key":"6562_CR120","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1084\/jem.189.11.1747","volume":"189","author":"P Schneider","year":"1999","unstructured":"Schneider P, MacKay F, Steiner V, et al. BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J Exp Med. 1999;189:1747\u20131756.","journal-title":"J Exp Med"},{"key":"6562_CR121","doi-asserted-by":"crossref","first-page":"5537","DOI":"10.4049\/jimmunol.174.9.5537","volume":"174","author":"AP Sutherland","year":"2005","unstructured":"Sutherland AP, Ng LG, Fletcher CA, et al. BAFF augments certain Th1-associated inflammatory responses. J Immunol. 2005;174:5537\u20135544.","journal-title":"J Immunol"},{"key":"6562_CR122","doi-asserted-by":"crossref","first-page":"e3194","DOI":"10.1097\/MD.0000000000003194","volume":"95","author":"H Nishikawa","year":"2016","unstructured":"Nishikawa H, Enomoto H, Iwata Y, et al. B-cell activating factor belonging to the tumor necrosis factor family and interferon-gamma-inducible protein-10 in autoimmune hepatitis. Medicine (Baltimore). 2016;95:e3194.","journal-title":"Medicine (Baltimore)"},{"key":"6562_CR123","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1038\/ni833","volume":"3","author":"S Fillatreau","year":"2002","unstructured":"Fillatreau S, Sweenie CH, McGeachy MJ, Gray D, Anderton SM. B cells regulate autoimmunity by provision of IL-10. Nat Immunol. 2002;3:944\u2013950.","journal-title":"Nat Immunol"},{"key":"6562_CR124","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1146\/annurev-immunol-020711-074934","volume":"30","author":"C Mauri","year":"2012","unstructured":"Mauri C, Bosma A. Immune regulatory function of B cells. Annu Rev Immunol. 2012;30:221\u2013241.","journal-title":"Annu Rev Immunol"},{"key":"6562_CR125","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1038\/cmi.2012.60","volume":"10","author":"M Yang","year":"2013","unstructured":"Yang M, Rui K, Wang S, Lu L. Regulatory B cells in autoimmune diseases. Cell Mol Immunol. 2013;10:122\u2013132.","journal-title":"Cell Mol Immunol"},{"key":"6562_CR126","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/j.semarthrit.2018.10.007","volume":"48","author":"LI Sakkas","year":"2019","unstructured":"Sakkas LI, Daoussis D, Mavropoulos A, Liossis SN, Bogdanos DP. Regulatory B cells: new players in inflammatory and autoimmune rheumatic diseases. Semin Arthritis Rheum. 2019;48:1133\u20131141.","journal-title":"Semin Arthritis Rheum"},{"key":"6562_CR127","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.immuni.2010.08.004","volume":"33","author":"TR Malek","year":"2010","unstructured":"Malek TR, Castro I. Interleukin-2 receptor signaling: at the interface between tolerance and immunity. Immunity. 2010;33:153\u2013165.","journal-title":"Immunity"},{"key":"6562_CR128","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1007\/978-1-4419-6451-9_3","volume":"684","author":"O Boyman","year":"2010","unstructured":"Boyman O, Cho JH, Sprent J. The role of interleukin-2 in memory CD8 cell differentiation. Adv Exp Med Biol. 2010;684:28\u201341.","journal-title":"Adv Exp Med Biol"},{"key":"6562_CR129","doi-asserted-by":"crossref","first-page":"5377","DOI":"10.1038\/ncomms6377","volume":"5","author":"KK McKinstry","year":"2014","unstructured":"McKinstry KK, Strutt TM, Bautista B, et al. Effector CD4 T-cell transition to memory requires late cognate interactions that induce autocrine IL-2. Nat Commun. 2014;5:5377.","journal-title":"Nat Commun"},{"key":"6562_CR130","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/978-3-540-68170-0_10","volume":"165","author":"AK Horst","year":"2004","unstructured":"Horst AK, Wagener C. CEA-related CAMs. Handb Exp Pharmacol. 2004;165:283\u2013341.","journal-title":"Handb Exp Pharmacol"},{"key":"6562_CR131","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1002\/hep.29812","volume":"68","author":"AK Horst","year":"2018","unstructured":"Horst AK, Wegscheid C, Schaefers C, et al. Carcinoembryonic antigen-related cell adhesion molecule 1 controls IL-2-dependent regulatory T-cell induction in immune-mediated hepatitis in mice. Hepatology. 2018;68:200\u2013214.","journal-title":"Hepatology"},{"key":"6562_CR132","doi-asserted-by":"crossref","first-page":"763","DOI":"10.4049\/jimmunol.160.2.763","volume":"160","author":"L Zheng","year":"1998","unstructured":"Zheng L, Trageser CL, Willerford DM, Lenardo MJ. T cell growth cytokines cause the superinduction of molecules mediating antigen-induced T lymphocyte death. J Immunol. 1998;160:763\u2013769.","journal-title":"J Immunol"},{"key":"6562_CR133","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/nri1864","volume":"6","author":"SD Gray-Owen","year":"2006","unstructured":"Gray-Owen SD, Blumberg RS. CEACAM1: contact-dependent control of immunity. Nat Rev Immunol. 2006;6:433\u2013446.","journal-title":"Nat Rev Immunol"},{"key":"6562_CR134","doi-asserted-by":"crossref","first-page":"3535","DOI":"10.4049\/jimmunol.172.6.3535","volume":"172","author":"D Chen","year":"2004","unstructured":"Chen D, Iijima H, Nagaishi T, et al. Carcinoembryonic antigen-related cellular adhesion molecule 1 isoforms alternatively inhibit and costimulate human T cell function. J Immunol. 2004;172:3535\u20133543.","journal-title":"J Immunol"},{"key":"6562_CR135","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1038\/377348a0","volume":"377","author":"L Zheng","year":"1995","unstructured":"Zheng L, Fisher G, Miller RE, et al. Induction of apoptosis in mature T cells by tumour necrosis factor. Nature. 1995;377:348\u2013351.","journal-title":"Nature"},{"key":"6562_CR136","doi-asserted-by":"crossref","first-page":"3055","DOI":"10.1002\/eji.1830261235","volume":"26","author":"DE Speiser","year":"1996","unstructured":"Speiser DE, Sebzda E, Ohteki T, et al. Tumor necrosis factor receptor p55 mediates deletion of peripheral cytotoxic T lymphocytes in vivo. Eur J Immunol. 1996;26:3055\u20133060.","journal-title":"Eur J Immunol"},{"key":"6562_CR137","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/S1074-7613(00)80566-X","volume":"8","author":"Y Refaeli","year":"1998","unstructured":"Refaeli Y, Van Parijs L, London CA, Tschopp J, Abbas AK. Biochemical mechanisms of IL-2-regulated Fas-mediated T cell apoptosis. Immunity. 1998;8:615\u2013623.","journal-title":"Immunity"},{"key":"6562_CR138","doi-asserted-by":"crossref","first-page":"3131","DOI":"10.4049\/jimmunol.163.6.3131","volume":"163","author":"Z Dai","year":"1999","unstructured":"Dai Z, Arakelov A, Wagener M, Konieczny BT, Lakkis FG. The role of the common cytokine receptor gamma-chain in regulating IL-2-dependent, activation-induced CD8+ T cell death. J Immunol. 1999;163:3131\u20133137.","journal-title":"J Immunol"},{"key":"6562_CR139","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1038\/353858a0","volume":"353","author":"MJ Lenardo","year":"1991","unstructured":"Lenardo MJ. Interleukin-2 programs mouse alpha beta T lymphocytes for apoptosis. Nature. 1991;353:858\u2013861.","journal-title":"Nature"},{"key":"6562_CR140","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1034\/j.1600-065X.2003.00051.x","volume":"193","author":"DR Green","year":"2003","unstructured":"Green DR, Droin N, Pinkoski M. Activation-induced cell death in T cells. Immunol Rev. 2003;193:70\u201381.","journal-title":"Immunol Rev"},{"key":"6562_CR141","doi-asserted-by":"crossref","first-page":"5538","DOI":"10.4049\/jimmunol.169.10.5538","volume":"169","author":"T Yamazaki","year":"2002","unstructured":"Yamazaki T, Akiba H, Iwai H, et al. Expression of programmed death 1 ligands by murine T cells and APC. J Immunol. 2002;169:5538\u20135545.","journal-title":"J Immunol"},{"key":"6562_CR142","doi-asserted-by":"crossref","first-page":"5336","DOI":"10.1073\/pnas.0931259100","volume":"100","author":"P Loke","year":"2003","unstructured":"Loke P, Allison JP. PD-L1 and PD-L2 are differentially regulated by Th1 and Th2 cells. Proc Natl Acad Sci U S A. 2003;100:5336\u20135341.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"6562_CR143","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1016\/j.celrep.2016.10.042","volume":"17","author":"TT Jiang","year":"2016","unstructured":"Jiang TT, Martinov T, Xin L, et al. Programmed death-1 culls peripheral accumulation of high-affinity autoreactive CD4 T cells to protect against autoimmunity. Cell Rep. 2016;17:1783\u20131794.","journal-title":"Cell Rep"},{"key":"6562_CR144","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1080\/08916934.2019.1641200","volume":"52","author":"AJ Czaja","year":"2019","unstructured":"Czaja AJ. Immune inhibitory proteins and their pathogenic and therapeutic implications in autoimmunity and autoimmune hepatitis. Autoimmunity. 2019;52:144\u2013160.","journal-title":"Autoimmunity"},{"key":"6562_CR145","doi-asserted-by":"crossref","first-page":"9331","DOI":"10.1073\/pnas.0710441105","volume":"105","author":"L Wang","year":"2008","unstructured":"Wang L, Pino-Lagos K, de Vries VC, et al. Programmed death 1 ligand signaling regulates the generation of adaptive Foxp3+CD4+ regulatory T cells. Proc Natl Acad Sci U S A. 2008;105:9331\u20139336.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"6562_CR146","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1189\/jlb.0813443","volume":"95","author":"SJ Park","year":"2014","unstructured":"Park SJ, Namkoong H, Doh J, et al. Negative role of inducible PD-1 on survival of activated dendritic cells. J Leukoc Biol. 2014;95:621\u2013629.","journal-title":"J Leukoc Biol"},{"key":"6562_CR147","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1093\/intimm\/dxp072","volume":"21","author":"W Wang","year":"2009","unstructured":"Wang W, Lau R, Yu D, et al. PD1 blockade reverses the suppression of melanoma antigen-specific CTL by CD4+ CD25(Hi) regulatory T cells. Int Immunol. 2009;21:1065\u20131077.","journal-title":"Int Immunol"},{"key":"6562_CR148","doi-asserted-by":"crossref","first-page":"10468","DOI":"10.1073\/pnas.1201131109","volume":"109","author":"J Gotot","year":"2012","unstructured":"Gotot J, Gottschalk C, Leopold S, et al. Regulatory T cells use programmed death 1 ligands to directly suppress autoreactive B cells in vivo. Proc Natl Acad Sci U S A. 2012;109:10468\u201310473.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"6562_CR149","doi-asserted-by":"crossref","first-page":"3581","DOI":"10.4049\/jimmunol.169.7.3581","volume":"169","author":"MM Mazanet","year":"2002","unstructured":"Mazanet MM, Hughes CC. B7-H1 is expressed by human endothelial cells and suppresses T cell cytokine synthesis. J Immunol. 2002;169:3581\u20133588.","journal-title":"J Immunol"},{"key":"6562_CR150","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1002\/1521-4141(200203)32:3<634::AID-IMMU634>3.0.CO;2-9","volume":"32","author":"L Carter","year":"2002","unstructured":"Carter L, Fouser LA, Jussif J, et al. PD-1:PD-L inhibitory pathway affects both CD4(+) and CD8(+) T cells and is overcome by IL-2. Eur J Immunol. 2002;32:634\u2013643.","journal-title":"Eur J Immunol"},{"key":"6562_CR151","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1200\/JCO.1999.17.7.2105","volume":"17","author":"MB Atkins","year":"1999","unstructured":"Atkins MB, Lotze MT, Dutcher JP, et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol. 1999;17:2105\u20132116.","journal-title":"J Clin Oncol"},{"key":"6562_CR152","doi-asserted-by":"crossref","first-page":"S51","DOI":"10.3747\/co.27.5135","volume":"27","author":"MG Smylie","year":"2020","unstructured":"Smylie MG. Use of immuno-oncology in melanoma. Curr Oncol. 2020;27:S51\u2013S58.","journal-title":"Curr Oncol"},{"key":"6562_CR153","doi-asserted-by":"crossref","first-page":"13027","DOI":"10.1038\/ncomms13027","volume":"7","author":"L Perol","year":"2016","unstructured":"Perol L, Lindner JM, Caudana P, et al. Loss of immune tolerance to IL-2 in type 1 diabetes. Nat Commun. 2016;7:13027.","journal-title":"Nat Commun"},{"key":"6562_CR154","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1212\/WNL.45.11.1971","volume":"45","author":"JL Trotter","year":"1995","unstructured":"Trotter JL, Damico CA, Trotter AL, Collins KG, Cross AH. Interleukin-2 binding proteins in sera from normal subjects and multiple sclerosis patients. Neurology. 1995;45:1971\u20131974.","journal-title":"Neurology"},{"key":"6562_CR155","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1007\/s00125-017-4376-2","volume":"60","author":"I Marzinotto","year":"2017","unstructured":"Marzinotto I, Liberati D, Brigatti C, et al. Autoantibody binding in liquid phase to IL-2 in human sera is not type 1 diabetes specific. Diabetologia. 2017;60:1834\u20131835.","journal-title":"Diabetologia"},{"key":"6562_CR156","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1007\/s00125-018-4649-4","volume":"61","author":"G Churlaud","year":"2018","unstructured":"Churlaud G, Rosenzwajg M, Cacoub P, et al. IL-2 antibodies in type 1 diabetes and during IL-2 therapy. Diabetologia. 2018;61:2066\u20132068.","journal-title":"Diabetologia"},{"key":"6562_CR157","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.immuni.2013.01.004","volume":"38","author":"W Liao","year":"2013","unstructured":"Liao W, Lin JX, Leonard WJ. Interleukin-2 at the crossroads of effector responses, tolerance, and immunotherapy. Immunity. 2013;38:13\u201325.","journal-title":"Immunity"},{"key":"6562_CR158","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1084\/jem.166.4.1055","volume":"166","author":"HM Wang","year":"1987","unstructured":"Wang HM, Smith KA. The interleukin 2 receptor. Functional consequences of its bimolecular structure. J Exp Med. 1987;166:1055\u20131069.","journal-title":"J Exp Med"},{"key":"6562_CR159","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/ng.728","volume":"43","author":"E Melum","year":"2011","unstructured":"Melum E, Franke A, Schramm C, et al. Genome-wide association analysis in primary sclerosing cholangitis identifies two non-HLA susceptibility loci. Nat Genet. 2011;43:17\u201319.","journal-title":"Nat Genet"},{"key":"6562_CR160","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1002\/hep.24307","volume":"53","author":"M Janse","year":"2011","unstructured":"Janse M, Lamberts LE, Franke L, et al. Three ulcerative colitis susceptibility loci are associated with primary sclerosing cholangitis and indicate a role for IL2, REL, and CARD9. Hepatology. 2011;53:1977\u20131985.","journal-title":"Hepatology"},{"key":"6562_CR161","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1016\/j.jhep.2013.12.027","volume":"60","author":"M Sebode","year":"2014","unstructured":"Sebode M, Peiseler M, Franke B, et al. Reduced FOXP3(+) regulatory T cells in patients with primary sclerosing cholangitis are associated with IL2RA gene polymorphisms. J Hepatol. 2014;60:1010\u20131016.","journal-title":"J Hepatol"},{"key":"6562_CR162","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1615\/CritRevImmunol.v18.i6.20","volume":"18","author":"YW He","year":"1998","unstructured":"He YW, Malek TR. The structure and function of gamma c-dependent cytokines and receptors: regulation of T lymphocyte development and homeostasis. Crit Rev Immunol. 1998;18:503\u2013524.","journal-title":"Crit Rev Immunol"},{"key":"6562_CR163","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1189\/jlb.72.5.856","volume":"72","author":"J Parrish-Novak","year":"2002","unstructured":"Parrish-Novak J, Foster DC, Holly RD, Clegg CH. Interleukin-21 and the IL-21 receptor: novel effectors of NK and T cell responses. J Leukoc Biol. 2002;72:856\u2013863.","journal-title":"J Leukoc Biol"},{"key":"6562_CR164","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1126\/science.8266076","volume":"262","author":"M Kondo","year":"1993","unstructured":"Kondo M, Takeshita T, Ishii N, et al. Sharing of the interleukin-2 (IL-2) receptor gamma chain between receptors for IL-2 and IL-4. Science. 1993;262:1874\u20131877.","journal-title":"Science"},{"key":"6562_CR165","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1126\/science.8128231","volume":"263","author":"M Kondo","year":"1994","unstructured":"Kondo M, Takeshita T, Higuchi M, et al. Functional participation of the IL-2 receptor gamma chain in IL-7 receptor complexes. Science. 1994;263:1453\u20131454.","journal-title":"Science"},{"key":"6562_CR166","doi-asserted-by":"crossref","first-page":"4940","DOI":"10.1073\/pnas.91.11.4940","volume":"91","author":"RN Bamford","year":"1994","unstructured":"Bamford RN, Grant AJ, Burton JD, et al. The interleukin (IL) 2 receptor beta chain is shared by IL-2 and a cytokine, provisionally designated IL-T, that stimulates T-cell proliferation and the induction of lymphokine-activated killer cells. Proc Natl Acad Sci U S A. 1994;91:4940\u20134944.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"6562_CR167","doi-asserted-by":"crossref","first-page":"2822","DOI":"10.1002\/j.1460-2075.1994.tb06576.x","volume":"13","author":"JG Giri","year":"1994","unstructured":"Giri JG, Ahdieh M, Eisenman J, et al. Utilization of the beta and gamma chains of the IL-2 receptor by the novel cytokine IL-15. EMBO J. 1994;13:2822\u20132830.","journal-title":"EMBO J"},{"key":"6562_CR168","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/35040504","volume":"408","author":"J Parrish-Novak","year":"2000","unstructured":"Parrish-Novak J, Dillon SR, Nelson A, et al. Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function. Nature. 2000;408:57\u201363.","journal-title":"Nature"},{"key":"6562_CR169","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/S1074-7613(00)80246-0","volume":"4","author":"Y Tagaya","year":"1996","unstructured":"Tagaya Y, Bamford RN, DeFilippis AP, Waldmann TA. IL-15: a pleiotropic cytokine with diverse receptor\/signaling pathways whose expression is controlled at multiple levels. Immunity. 1996;4:329\u2013336.","journal-title":"Immunity"},{"key":"6562_CR170","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1084\/jem.191.5.753","volume":"191","author":"A Ma","year":"2000","unstructured":"Ma A, Boone DL, Lodolce JP. The pleiotropic functions of interleukin 15: not so interleukin 2-like after all. J Exp Med. 2000;191:753\u2013756.","journal-title":"J Exp Med"},{"key":"6562_CR171","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/S1074-7613(00)80664-0","volume":"9","author":"JP Lodolce","year":"1998","unstructured":"Lodolce JP, Boone DL, Chai S, et al. IL-15 receptor maintains lymphoid homeostasis by supporting lymphocyte homing and proliferation. Immunity. 1998;9:669\u2013676.","journal-title":"Immunity"},{"key":"6562_CR172","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1084\/jem.191.5.771","volume":"191","author":"MK Kennedy","year":"2000","unstructured":"Kennedy MK, Glaccum M, Brown SN, et al. Reversible defects in natural killer and memory CD8 T cell lineages in interleukin 15-deficient mice. J Exp Med. 2000;191:771\u2013780.","journal-title":"J Exp Med"},{"key":"6562_CR173","doi-asserted-by":"crossref","first-page":"3285","DOI":"10.4049\/jimmunol.181.5.3285","volume":"181","author":"KB Vang","year":"2008","unstructured":"Vang KB, Yang J, Mahmud SA, et al. IL-2, -7, and -15, but not thymic stromal lymphopoeitin, redundantly govern CD4+Foxp3+ regulatory T cell development. J Immunol. 2008;181:3285\u20133290.","journal-title":"J Immunol"},{"key":"6562_CR174","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1155\/S0962935193000018","volume":"2","author":"C Caruso","year":"1993","unstructured":"Caruso C, Candore G, Cigna D, Colucci AT, Modica MA. Biological significance of soluble IL-2 receptor. Mediat Inflamm. 1993;2:3\u201321.","journal-title":"Mediat Inflamm"},{"key":"6562_CR175","doi-asserted-by":"crossref","first-page":"3172","DOI":"10.4049\/jimmunol.135.5.3172","volume":"135","author":"LA Rubin","year":"1985","unstructured":"Rubin LA, Kurman CC, Fritz ME, et al. Soluble interleukin 2 receptors are released from activated human lymphoid cells in vitro. J Immunol. 1985;135:3172\u20133177.","journal-title":"J Immunol"},{"key":"6562_CR176","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1007\/BF00918743","volume":"6","author":"DL Nelson","year":"1986","unstructured":"Nelson DL, Rubin LA, Kurman CC, Fritz ME, Boutin B. An analysis of the cellular requirements for the production of soluble interleukin-2 receptors in vitro. J Clin Immunol. 1986;6:114\u2013120.","journal-title":"J Clin Immunol"},{"key":"6562_CR177","doi-asserted-by":"crossref","first-page":"619","DOI":"10.7326\/0003-4819-113-8-619","volume":"113","author":"LA Rubin","year":"1990","unstructured":"Rubin LA, Nelson DL. The soluble interleukin-2 receptor: biology, function, and clinical application. Ann Intern Med. 1990;113:619\u2013627.","journal-title":"Ann Intern Med"},{"key":"6562_CR178","doi-asserted-by":"crossref","first-page":"4099","DOI":"10.4049\/jimmunol.136.11.4099","volume":"136","author":"BF Treiger","year":"1986","unstructured":"Treiger BF, Leonard WJ, Svetlik P, et al. A secreted form of the human interleukin 2 receptor encoded by an \u201canchor minus\u201d cDNA. J Immunol. 1986;136:4099\u20134105.","journal-title":"J Immunol"},{"key":"6562_CR179","doi-asserted-by":"crossref","first-page":"3841","DOI":"10.4049\/jimmunol.137.12.3841","volume":"137","author":"LA Rubin","year":"1986","unstructured":"Rubin LA, Jay G, Nelson DL. The released interleukin 2 receptor binds interleukin 2 efficiently. J Immunol. 1986;137:3841\u20133844.","journal-title":"J Immunol"},{"key":"6562_CR180","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1136\/gut.31.6.690","volume":"31","author":"A Lobo-Yeo","year":"1990","unstructured":"Lobo-Yeo A, Mieli-Vergani G, Mowat AP, Vergani D. Soluble interleukin 2 receptors in autoimmune chronic active hepatitis. Gut. 1990;31:690\u2013693.","journal-title":"Gut"},{"key":"6562_CR181","doi-asserted-by":"crossref","first-page":"129","DOI":"10.3109\/08916939008993385","volume":"7","author":"MN Manoussakis","year":"1990","unstructured":"Manoussakis MN, Stavropoulos ED, Germanidis GS, et al. Soluble interleukin-2 receptors and autoantibodies in the serum of healthy elderly individuals. Autoimmunity. 1990;7:129\u2013137.","journal-title":"Autoimmunity"},{"key":"6562_CR182","first-page":"161","volume":"68","author":"DJ Giannitsis","year":"1991","unstructured":"Giannitsis DJ, Muller-Hof B, Hacker-Shahin B. Serum soluble interleukin-2 receptor levels of normal blood donors. Cytobios. 1991;68:161\u2013164.","journal-title":"Cytobios"},{"key":"6562_CR183","first-page":"335","volume":"3","author":"B Lemmer","year":"1992","unstructured":"Lemmer B, Schwulera U, Thrun A, Lissner R. Circadian rhythm of soluble interleukin-2 receptor in healthy individuals. Eur Cytokine Netw. 1992;3:335\u2013336.","journal-title":"Eur Cytokine Netw"},{"key":"6562_CR184","first-page":"183","volume":"60","author":"D Dejica","year":"2001","unstructured":"Dejica D. Serum soluble IL-2 receptor as a marker of lymphocyte activation in some autoimmune diseases. Effect of immunosuppressive therapy. Roum Arch Microbiol Immunol. 2001;60:183\u2013201.","journal-title":"Roum Arch Microbiol Immunol"},{"key":"6562_CR185","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1056\/NEJM198812223192527","volume":"319","author":"SA Rosenberg","year":"1988","unstructured":"Rosenberg SA, Packard BS, Aebersold PM, et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N Engl J Med. 1988;319:1676\u20131680.","journal-title":"N Engl J Med"},{"key":"6562_CR186","first-page":"4","volume":"16","author":"JP Dutcher","year":"2002","unstructured":"Dutcher JP. Current status of interleukin-2 therapy for metastatic renal cell carcinoma and metastatic melanoma. Oncology (Williston Park). 2002;16:4\u201310.","journal-title":"Oncology (Williston Park)"},{"key":"6562_CR187","doi-asserted-by":"crossref","first-page":"5451","DOI":"10.4049\/jimmunol.1490019","volume":"192","author":"SA Rosenberg","year":"2014","unstructured":"Rosenberg SA. IL-2: the first effective immunotherapy for human cancer. J Immunol. 2014;192:5451\u20135458.","journal-title":"J Immunol"},{"key":"6562_CR188","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1080\/14740338.2017.1382472","volume":"16","author":"S Marabondo","year":"2017","unstructured":"Marabondo S, Kaufman HL. High-dose interleukin-2 (IL-2) for the treatment of melanoma: safety considerations and future directions. Expert Opin Drug Saf. 2017;16:1347\u20131357.","journal-title":"Expert Opin Drug Saf"},{"key":"6562_CR189","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/S0090-4295(99)80414-2","volume":"47","author":"KL Shulman","year":"1996","unstructured":"Shulman KL, Stadler WM, Vogelzang NJ. High-dose continuous intravenous infusion of interleukin-2 therapy for metastatic renal cell carcinoma: the University of Chicago experience. Urology. 1996;47:194\u2013197.","journal-title":"Urology"},{"key":"6562_CR190","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1200\/JCO.1994.12.8.1572","volume":"12","author":"JC Yang","year":"1994","unstructured":"Yang JC, Topalian SL, Parkinson D, et al. Randomized comparison of high-dose and low-dose intravenous interleukin-2 for the therapy of metastatic renal cell carcinoma: an interim report. J Clin Oncol. 1994;12:1572\u20131576.","journal-title":"J Clin Oncol"},{"key":"6562_CR191","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s40425-014-0026-0","volume":"2","author":"JP Dutcher","year":"2014","unstructured":"Dutcher JP, Schwartzentruber DJ, Kaufman HL, et al. High dose interleukin-2 (Aldesleukin)\u2014expert consensus on best management practices-2014. J Immunother Cancer. 2014;2:26.","journal-title":"J Immunother Cancer"},{"key":"6562_CR192","doi-asserted-by":"crossref","first-page":"143","DOI":"10.3390\/jcm8020143","volume":"8","author":"GH Jeong","year":"2019","unstructured":"Jeong GH, Lee KH, Lee IR, et al. Incidence of capillary leak syndrome as an adverse effect of drugs in cancer patients: a systematic review and meta-analysis. J Clin Med. 2019;8:143.","journal-title":"J Clin Med"},{"key":"6562_CR193","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1001\/jamadermatol.2014.510","volume":"150","author":"M Hordinsky","year":"2014","unstructured":"Hordinsky M, Kaplan DH. Low-dose interleukin 2 to reverse alopecia areata. JAMA Dermatol. 2014;150:696\u2013697.","journal-title":"JAMA Dermatol"},{"key":"6562_CR194","first-page":"541","volume":"63","author":"S Saxena","year":"1986","unstructured":"Saxena S, Nouri-Aria KT, Anderson MG, Eddleston AL, Williams R. Interleukin 2 activity in chronic liver disease and the effect of in vitro alpha-interferon. Clin Exp Immunol. 1986;63:541\u2013548.","journal-title":"Clin Exp Immunol"},{"key":"6562_CR195","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/0091-6749(93)90068-Q","volume":"92","author":"A Al-Wabel","year":"1993","unstructured":"Al-Wabel A, Al-Janadi M, Raziuddin S. Cytokine profile of viral and autoimmune chronic active hepatitis. J Allergy Clin Immunol. 1993;92:902\u2013908.","journal-title":"J Allergy Clin Immunol"},{"key":"6562_CR196","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1023\/A:1005506031717","volume":"45","author":"AJ Czaja","year":"2000","unstructured":"Czaja AJ, Sievers C, Zein NN. Nature and behavior of serum cytokines in type 1 autoimmune hepatitis. Dig Dis Sci. 2000;45:1028\u20131035. https:\/\/doi.org\/10.1023\/A:1005506031717.","journal-title":"Dig Dis Sci"},{"key":"6562_CR197","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1002\/hep.27884","volume":"62","author":"R Liberal","year":"2015","unstructured":"Liberal R, Grant CR, Holder BS, et al. In autoimmune hepatitis type 1 or the autoimmune hepatitis-sclerosing cholangitis variant defective regulatory T-cell responsiveness to IL-2 results in low IL-10 production and impaired suppression. Hepatology. 2015;62:863\u2013875.","journal-title":"Hepatology"},{"key":"6562_CR198","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1002\/hep.25682","volume":"56","author":"R Liberal","year":"2012","unstructured":"Liberal R, Grant CR, Holder BS, et al. The impaired immune regulation of autoimmune hepatitis is linked to a defective galectin-9\/tim-3 pathway. Hepatology. 2012;56:677\u2013686.","journal-title":"Hepatology"},{"key":"6562_CR199","doi-asserted-by":"crossref","first-page":"e38708","DOI":"10.1371\/journal.pone.0038708","volume":"7","author":"GM Vaitaitis","year":"2012","unstructured":"Vaitaitis GM, Wagner DH Jr. Galectin-9 controls CD40 signaling through a Tim-3 independent mechanism and redirects the cytokine profile of pathogenic T cells in autoimmunity. PLoS One. 2012;7:e38708.","journal-title":"PLoS One"},{"key":"6562_CR200","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.jaut.2005.05.001","volume":"25","author":"MS Longhi","year":"2005","unstructured":"Longhi MS, Ma Y, Mitry RR, et al. Effect of CD4+ CD25+ regulatory T-cells on CD8 T-cell function in patients with autoimmune hepatitis. J Autoimmun. 2005;25:63\u201371.","journal-title":"J Autoimmun"},{"key":"6562_CR201","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1038\/s41598-017-18818-5","volume":"8","author":"J Diestelhorst","year":"2018","unstructured":"Diestelhorst J, Junge N, Jonigk D, et al. Baseline IL-2 and the AIH score can predict the response to standard therapy in paediatric autoimmune hepatitis. Sci Rep. 2018;8:419.","journal-title":"Sci Rep"},{"key":"6562_CR202","doi-asserted-by":"crossref","first-page":"e0181107","DOI":"10.1371\/journal.pone.0181107","volume":"12","author":"J Diestelhorst","year":"2017","unstructured":"Diestelhorst J, Junge N, Schlue J, et al. Pediatric autoimmune hepatitis shows a disproportionate decline of regulatory T cells in the liver and of IL-2 in the blood of patients undergoing therapy. PLoS ONE. 2017;12:e0181107.","journal-title":"PLoS ONE"},{"key":"6562_CR203","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1016\/j.jhep.2014.05.034","volume":"61","author":"R Taubert","year":"2014","unstructured":"Taubert R, Hardtke-Wolenski M, Noyan F, et al. Intrahepatic regulatory T cells in autoimmune hepatitis are associated with treatment response and depleted with current therapies. J Hepatol. 2014;61:1106\u20131114.","journal-title":"J Hepatol"},{"key":"6562_CR204","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.clinre.2017.06.005","volume":"42","author":"A Yousefi","year":"2018","unstructured":"Yousefi A, Mahmoudi E, Baradaran Noveiry B, et al. Autoimmune hepatitis association with single nucleotide polymorphism of interleukin-2, but not interferon-gamma. Clin Res Hepatol Gastroenterol. 2018;42:134\u2013138.","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"6562_CR205","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.clim.2017.12.004","volume":"188","author":"D Mele","year":"2018","unstructured":"Mele D, Bossi G, Maggiore G, et al. Altered natural killer cell cytokine profile in type 2 autoimmune hepatitis. Clin Immunol. 2018;188:31\u201337.","journal-title":"Clin Immunol"},{"key":"6562_CR206","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/S1471-4906(01)02060-9","volume":"22","author":"MA Cooper","year":"2001","unstructured":"Cooper MA, Fehniger TA, Caligiuri MA. The biology of human natural killer-cell subsets. Trends Immunol. 2001;22:633\u2013640.","journal-title":"Trends Immunol"},{"key":"6562_CR207","first-page":"455","volume":"7","author":"KJ Simpson","year":"1995","unstructured":"Simpson KJ, Jones AL, Forbes Howie A, Hayes PC. Soluble adhesion molecules and interleukin-2 receptor concentrations in patients with autoimmune chronic hepatitis. Eur J Gastroenterol Hepatol. 1995;7:455\u2013460.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"6562_CR208","first-page":"15","volume":"35","author":"D Dejica","year":"1997","unstructured":"Dejica D, Treichel U, Par A, Chira O, Meyer zum Buschenfelde KH. Anti asialoglycoprotein receptor antibodies and soluble interleukin-2 receptor levels as marker for inflammation in autoimmune hepatitis. Z Gastroenterol. 1997;35:15\u201321.","journal-title":"Z Gastroenterol"},{"key":"6562_CR209","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1128\/CMR.9.4.532","volume":"9","author":"DR Lucey","year":"1996","unstructured":"Lucey DR, Clerici M, Shearer GM. Type 1 and type 2 cytokine dysregulation in human infectious, neoplastic, and inflammatory diseases. Clin Microbiol Rev. 1996;9:532\u2013562.","journal-title":"Clin Microbiol Rev"},{"key":"6562_CR210","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1002\/hep.510230436","volume":"23","author":"M Peters","year":"1996","unstructured":"Peters M. Actions of cytokines on the immune response and viral interactions: an overview. Hepatology. 1996;23:909\u2013916.","journal-title":"Hepatology"},{"key":"6562_CR211","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/nri3464","volume":"13","author":"S Sakaguchi","year":"2013","unstructured":"Sakaguchi S, Vignali DA, Rudensky AY, Niec RE, Waldmann H. The plasticity and stability of regulatory T cells. Nat Rev Immunol. 2013;13:461\u2013467.","journal-title":"Nat Rev Immunol"},{"key":"6562_CR212","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/nature04753","volume":"441","author":"E Bettelli","year":"2006","unstructured":"Bettelli E, Carrier Y, Gao W, et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature. 2006;441:235\u2013238.","journal-title":"Nature"},{"key":"6562_CR213","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1038\/ni1539","volume":"8","author":"MJ McGeachy","year":"2007","unstructured":"McGeachy MJ, Bak-Jensen KS, Chen Y, et al. TGF-beta and IL-6 drive the production of IL-17 and IL-10 by T cells and restrain T(H)-17 cell-mediated pathology. Nat Immunol. 2007;8:1390\u20131397.","journal-title":"Nat Immunol"},{"key":"6562_CR214","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.molimm.2008.12.019","volume":"47","author":"S Romagnani","year":"2009","unstructured":"Romagnani S, Maggi E, Liotta F, Cosmi L, Annunziato F. Properties and origin of human Th17 cells. Mol Immunol. 2009;47:3\u20137.","journal-title":"Mol Immunol"},{"key":"6562_CR215","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1111\/j.1365-2249.2009.04038.x","volume":"159","author":"B Afzali","year":"2010","unstructured":"Afzali B, Mitchell P, Lechler RI, John S, Lombardi G. Translational mini-review series on Th17 cells: induction of interleukin-17 production by regulatory T cells. Clin Exp Immunol. 2010;159:120\u2013130.","journal-title":"Clin Exp Immunol"},{"key":"6562_CR216","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1038\/nature09447","volume":"467","author":"K Ghoreschi","year":"2010","unstructured":"Ghoreschi K, Laurence A, Yang XP, et al. Generation of pathogenic T(H)17 cells in the absence of TGF-beta signalling. Nature. 2010;467:967\u2013971.","journal-title":"Nature"},{"key":"6562_CR217","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1002\/eji.201040391","volume":"40","author":"A Kimura","year":"2010","unstructured":"Kimura A, Kishimoto T. IL-6: regulator of Treg\/Th17 balance. Eur J Immunol. 2010;40:1830\u20131835.","journal-title":"Eur J Immunol"},{"key":"6562_CR218","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/ni.2416","volume":"13","author":"Y Lee","year":"2012","unstructured":"Lee Y, Awasthi A, Yosef N, et al. Induction and molecular signature of pathogenic TH17 cells. Nat Immunol. 2012;13:991\u2013999.","journal-title":"Nat Immunol"},{"key":"6562_CR219","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/nature14452","volume":"523","author":"N Gagliani","year":"2015","unstructured":"Gagliani N, Amezcua Vesely MC, Iseppon A, et al. Th17 cells transdifferentiate into regulatory T cells during resolution of inflammation. Nature. 2015;523:221\u2013225.","journal-title":"Nature"},{"key":"6562_CR220","doi-asserted-by":"crossref","first-page":"35283","DOI":"10.1074\/jbc.C109.078238","volume":"284","author":"GJ Martinez","year":"2009","unstructured":"Martinez GJ, Zhang Z, Chung Y, et al. Smad3 differentially regulates the induction of regulatory and inflammatory T cell differentiation. J Biol Chem. 2009;284:35283\u201335286.","journal-title":"J Biol Chem"},{"key":"6562_CR221","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1002\/hep.28517","volume":"64","author":"YY Chen","year":"2016","unstructured":"Chen YY, Jeffery HC, Hunter S, et al. Human intrahepatic regulatory T cells are functional, require IL-2 from effector cells for survival, and are susceptible to Fas ligand-mediated apoptosis. Hepatology. 2016;64:138\u2013150.","journal-title":"Hepatology"},{"key":"6562_CR222","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1002\/hep.27131","volume":"60","author":"DA Mann","year":"2014","unstructured":"Mann DA. Epigenetics in liver disease. Hepatology. 2014;60:1418\u20131425.","journal-title":"Hepatology"},{"key":"6562_CR223","doi-asserted-by":"crossref","first-page":"e12899","DOI":"10.1111\/eci.12899","volume":"48","author":"AJ Czaja","year":"2018","unstructured":"Czaja AJ. Epigenetic changes and their implications in autoimmune hepatitis. Eur J Clin Investig. 2018;48:e12899.","journal-title":"Eur J Clin Investig"},{"key":"6562_CR224","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1002\/hep.27793","volume":"62","author":"F Heymann","year":"2015","unstructured":"Heymann F, Peusquens J, Ludwig-Portugall I, et al. Liver inflammation abrogates immunological tolerance induced by Kupffer cells. Hepatology. 2015;62:279\u2013291.","journal-title":"Hepatology"},{"key":"6562_CR225","doi-asserted-by":"crossref","first-page":"194","DOI":"10.3810\/pgm.2011.09.2475","volume":"123","author":"CA Umscheid","year":"2011","unstructured":"Umscheid CA, Margolis DJ, Grossman CE. Key concepts of clinical trials: a narrative review. Postgrad Med. 2011;123:194\u2013204.","journal-title":"Postgrad Med"},{"key":"6562_CR226","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1097\/CJI.0b013e31821dcb50","volume":"34","author":"WE Samlowski","year":"2011","unstructured":"Samlowski WE, Kondapaneni M, Tharkar S, et al. Endothelial nitric oxide synthase is a key mediator of interleukin-2-induced hypotension and vascular leak syndrome. J Immunother. 2011;34:419\u2013427.","journal-title":"J Immunother"},{"key":"6562_CR227","first-page":"13","volume":"63","author":"PV Sivakumar","year":"2013","unstructured":"Sivakumar PV, Garcia R, Waggie KS, et al. Comparison of vascular leak syndrome in mice treated with IL21 or IL2. Comp Med. 2013;63:13\u201321.","journal-title":"Comp Med"},{"key":"6562_CR228","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1177\/172460089000500405","volume":"5","author":"P Lissoni","year":"1990","unstructured":"Lissoni P, Barni S, Cattaneo G, et al. Activation of the complement system during immunotherapy of cancer with interleukin-2: a possible explanation of the capillary leak syndrome. Int J Biol Markers. 1990;5:195\u2013197.","journal-title":"Int J Biol Markers"},{"key":"6562_CR229","doi-asserted-by":"crossref","first-page":"475","DOI":"10.7326\/0003-4819-113-6-475","volume":"113","author":"M Cicardi","year":"1990","unstructured":"Cicardi M, Gardinali M, Bisiani G, et al. The systemic capillary leak syndrome: appearance of interleukin-2-receptor-positive cells during attacks. Ann Intern Med. 1990;113:475\u2013477.","journal-title":"Ann Intern Med"},{"key":"6562_CR230","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1067\/mjd.2001.110643","volume":"44","author":"M Acosta","year":"2001","unstructured":"Acosta M, Teitelbaum A. Capillary leak syndrome in a patient treated with interleukin 2 fusion toxin for cutaneous T-cell lymphoma. J Am Acad Dermatol. 2001;44:312\u2013313.","journal-title":"J Am Acad Dermatol"},{"key":"6562_CR231","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1080\/00365520802130183","volume":"43","author":"M Werner","year":"2008","unstructured":"Werner M, Prytz H, Ohlsson B, et al. Epidemiology and the initial presentation of autoimmune hepatitis in Sweden: a nationwide study. Scand J Gastroenterol. 2008;43:1232\u20131240.","journal-title":"Scand J Gastroenterol"},{"key":"6562_CR232","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1053\/gast.1996.v110.pm8608895","volume":"110","author":"SK Roberts","year":"1996","unstructured":"Roberts SK, Therneau TM, Czaja AJ. Prognosis of histological cirrhosis in type 1 autoimmune hepatitis. Gastroenterology. 1996;110:848\u2013857.","journal-title":"Gastroenterology"},{"key":"6562_CR233","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1111\/j.1572-0241.2004.30457.x","volume":"99","author":"S Verma","year":"2004","unstructured":"Verma S, Gunuwan B, Mendler M, Govindrajan S, Redeker A. Factors predicting relapse and poor outcome in type I autoimmune hepatitis: role of cirrhosis development, patterns of transaminases during remission and plasma cell activity in the liver biopsy. Am J Gastroenterol. 2004;99:1510\u20131516.","journal-title":"Am J Gastroenterol"},{"key":"6562_CR234","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/0016-5085(79)90212-9","volume":"77","author":"AJ Czaja","year":"1979","unstructured":"Czaja AJ, Wolf AM, Summerskill WH. Development and early prognosis of esophageal varices in severe chronic active liver disease (CALD) treated with prednisone. Gastroenterology. 1979;77:629\u2013633.","journal-title":"Gastroenterology"},{"key":"6562_CR235","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1080\/17474124.2018.1453356","volume":"12","author":"AJ Czaja","year":"2018","unstructured":"Czaja AJ. Emerging therapeutic biomarkers of autoimmune hepatitis and their impact on current and future management. Expert Rev Gastroenterol Hepatol. 2018;12:547\u2013564.","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"6562_CR236","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/j.1600-065X.2006.00435.x","volume":"213","author":"IN Crispe","year":"2006","unstructured":"Crispe IN, Giannandrea M, Klein I, et al. Cellular and molecular mechanisms of liver tolerance. Immunol Rev. 2006;213:101\u2013118.","journal-title":"Immunol Rev"},{"key":"6562_CR237","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1146\/annurev.immunol.021908.132629","volume":"27","author":"IN Crispe","year":"2009","unstructured":"Crispe IN. The liver as a lymphoid organ. Annu Rev Immunol. 2009;27:147\u2013163.","journal-title":"Annu Rev Immunol"},{"key":"6562_CR238","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1002\/hep.27254","volume":"60","author":"IN Crispe","year":"2014","unstructured":"Crispe IN. Immune tolerance in liver disease. Hepatology. 2014;60:2109\u20132117.","journal-title":"Hepatology"},{"key":"6562_CR239","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.3389\/fimmu.2019.02525","volume":"10","author":"M Zheng","year":"2019","unstructured":"Zheng M, Tian Z. Liver-mediated adaptive immune tolerance. Front Immunol. 2019;10:2525.","journal-title":"Front Immunol"},{"key":"6562_CR240","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1097\/TP.0000000000002690","volume":"103","author":"S Chaudhry","year":"2019","unstructured":"Chaudhry S, Emond J, Griesemer A. Immune cell trafficking to the liver. Transplantation. 2019;103:1323\u20131337.","journal-title":"Transplantation"},{"key":"6562_CR241","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.3389\/fimmu.2020.01044","volume":"11","author":"H Dai","year":"2020","unstructured":"Dai H, Zheng Y, Thomson AW, Rogers NM. Transplant tolerance induction: insights from the liver. Front Immunol. 2020;11:1044.","journal-title":"Front Immunol"},{"key":"6562_CR242","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/imm.13193","volume":"160","author":"Z Stamataki","year":"2020","unstructured":"Stamataki Z, Swadling L. The liver as an immunological barrier redefined by single-cell analysis. Immunology. 2020;160:157\u2013170.","journal-title":"Immunology"},{"key":"6562_CR243","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.4049\/jimmunol.174.4.2037","volume":"174","author":"A De Creus","year":"2005","unstructured":"De Creus A, Abe M, Lau AH, et al. Low TLR4 expression by liver dendritic cells correlates with reduced capacity to activate allogeneic T cells in response to endotoxin. J Immunol. 2005;174:2037\u20132045.","journal-title":"J Immunol"},{"key":"6562_CR244","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.4049\/jimmunol.172.2.1009","volume":"172","author":"VG Pillarisetty","year":"2004","unstructured":"Pillarisetty VG, Shah AB, Miller G, Bleier JI, DeMatteo RP. Liver dendritic cells are less immunogenic than spleen dendritic cells because of differences in subtype composition. J Immunol. 2004;172:1009\u20131017.","journal-title":"J Immunol"},{"key":"6562_CR245","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.jhep.2005.08.010","volume":"44","author":"F Cabillic","year":"2006","unstructured":"Cabillic F, Rougier N, Basset C, et al. Hepatic environment elicits monocyte differentiation into a dendritic cell subset directing Th2 response. J Hepatol. 2006;44:552\u2013559.","journal-title":"J Hepatol"},{"key":"6562_CR246","doi-asserted-by":"crossref","first-page":"5453","DOI":"10.4049\/jimmunol.153.12.5453","volume":"153","author":"CR Roland","year":"1994","unstructured":"Roland CR, Walp L, Stack RM, Flye MW. Outcome of Kupffer cell antigen presentation to a cloned murine Th1 lymphocyte depends on the inducibility of nitric oxide synthase by IFN-gamma. J Immunol. 1994;153:5453\u20135464.","journal-title":"J Immunol"},{"key":"6562_CR247","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/S0168-8278(98)80206-7","volume":"28","author":"S Norris","year":"1998","unstructured":"Norris S, Collins C, Doherty DG, et al. Resident human hepatic lymphocytes are phenotypically different from circulating lymphocytes. J Hepatol. 1998;28:84\u201390.","journal-title":"J Hepatol"},{"key":"6562_CR248","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1002\/(SICI)1521-4141(199801)28:01<221::AID-IMMU221>3.0.CO;2-F","volume":"28","author":"P Bertolino","year":"1998","unstructured":"Bertolino P, Trescol-Biemont MC, Rabourdin-Combe C. Hepatocytes induce functional activation of naive CD8+ T lymphocytes but fail to promote survival. Eur J Immunol. 1998;28:221\u2013236.","journal-title":"Eur J Immunol"},{"key":"6562_CR249","doi-asserted-by":"crossref","first-page":"946","DOI":"10.3389\/fimmu.2019.00946","volume":"10","author":"J Mikulak","year":"2019","unstructured":"Mikulak J, Bruni E, Oriolo F, Di Vito C, Mavilio D. Hepatic natural killer cells: organ-specific sentinels of liver immune homeostasis and physiopathology. Front Immunol. 2019;10:946.","journal-title":"Front Immunol"},{"key":"6562_CR250","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1146\/annurev.immunol.25.022106.141711","volume":"25","author":"A Bendelac","year":"2007","unstructured":"Bendelac A, Savage PB, Teyton L. The biology of NKT cells. Annu Rev Immunol. 2007;25:297\u2013336.","journal-title":"Annu Rev Immunol"},{"key":"6562_CR251","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S0167-5699(00)01735-7","volume":"21","author":"DI Godfrey","year":"2000","unstructured":"Godfrey DI, Hammond KJ, Poulton LD, Smyth MJ, Baxter AG. NKT cells: facts, functions and fallacies. Immunol Today. 2000;21:573\u2013583.","journal-title":"Immunol Today"},{"key":"6562_CR252","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/nri854","volume":"2","author":"M Kronenberg","year":"2002","unstructured":"Kronenberg M, Gapin L. The unconventional lifestyle of NKT cells. Nat Rev Immunol. 2002;2:557\u2013568.","journal-title":"Nat Rev Immunol"},{"key":"6562_CR253","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/nri1309","volume":"4","author":"DI Godfrey","year":"2004","unstructured":"Godfrey DI, MacDonald HR, Kronenberg M, Smyth MJ, Van Kaer L. NKT cells: what\u2019s in a name? Nat Rev Immunol. 2004;4:231\u2013237.","journal-title":"Nat Rev Immunol"},{"key":"6562_CR254","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1080\/08830180601070195","volume":"26","author":"M Nowak","year":"2007","unstructured":"Nowak M, Stein-Streilein J. Invariant NKT cells and tolerance. Int Rev Immunol. 2007;26:95\u2013119.","journal-title":"Int Rev Immunol"},{"key":"6562_CR255","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/nri2904","volume":"11","author":"SP Berzins","year":"2011","unstructured":"Berzins SP, Smyth MJ, Baxter AG. Presumed guilty: natural killer T cell defects and human disease. Nat Rev Immunol. 2011;11:131\u2013142.","journal-title":"Nat Rev Immunol"},{"key":"6562_CR256","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.bbrc.2011.06.193","volume":"411","author":"KH Oh","year":"2011","unstructured":"Oh KH, Lee C, Lee SW, et al. Activation of natural killer T cells inhibits the development of induced regulatory T cells via IFNgamma. Biochem Biophys Res Commun. 2011;411:599\u2013606.","journal-title":"Biochem Biophys Res Commun"},{"key":"6562_CR257","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1038\/ni1380","volume":"7","author":"Y Kinjo","year":"2006","unstructured":"Kinjo Y, Tupin E, Wu D, et al. Natural killer T cells recognize diacylglycerol antigens from pathogenic bacteria. Nat Immunol. 2006;7:978\u2013986.","journal-title":"Nat Immunol"},{"key":"6562_CR258","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/j.1365-2249.2007.03415.x","volume":"149","author":"Z Tu","year":"2007","unstructured":"Tu Z, Bozorgzadeh A, Crispe IN, Orloff MS. The activation state of human intrahepatic lymphocytes. Clin Exp Immunol. 2007;149:186\u2013193.","journal-title":"Clin Exp Immunol"},{"key":"6562_CR259","doi-asserted-by":"crossref","first-page":"S114","DOI":"10.1016\/j.molmet.2019.06.025","volume":"27S","author":"L Bertrand","year":"2019","unstructured":"Bertrand L, Lehuen A. MAIT cells in metabolic diseases. Mol Metab. 2019;27S:S114\u2013S121.","journal-title":"Mol Metab"},{"key":"6562_CR260","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/nri2781","volume":"10","author":"M Bonneville","year":"2010","unstructured":"Bonneville M, O\u2019Brien RL, Born WK. Gammadelta T cell effector functions: a blend of innate programming and acquired plasticity. Nat Rev Immunol. 2010;10:467\u2013478.","journal-title":"Nat Rev Immunol"},{"key":"6562_CR261","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1053\/gast.1996.v110.pm8536867","volume":"110","author":"DS Pratt","year":"1996","unstructured":"Pratt DS, Flavin DP, Kaplan MM. The successful treatment of autoimmune hepatitis with 6-mercaptopurine after failure with azathioprine. Gastroenterology. 1996;110:271\u2013274.","journal-title":"Gastroenterology"},{"key":"6562_CR262","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.cgh.2015.09.037","volume":"14","author":"S Hubener","year":"2016","unstructured":"Hubener S, Oo YH, Than NN, et al. Efficacy of 6-mercaptopurine as second-line treatment for patients with autoimmune hepatitis and azathioprine intolerance. Clin Gastroenterol Hepatol. 2016;14:445\u2013453.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"6562_CR263","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1016\/j.cgh.2017.06.001","volume":"15","author":"C Efe","year":"2017","unstructured":"Efe C, Hagstrom H, Ytting H, et al. Efficacy and safety of mycophenolate mofetil and tacrolimus as second-line therapy for patients with autoimmune hepatitis. Clin Gastroenterol Hepatol. 2017;15:1950\u20131956.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"6562_CR264","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.cgh.2017.09.063","volume":"16","author":"SK Roberts","year":"2018","unstructured":"Roberts SK, Lim R, Strasser S, et al. Efficacy and safety of mycophenolate mofetil in patients with autoimmune hepatitis and suboptimal outcomes after standard therapy. Clin Gastroenterol Hepatol. 2018;16:268\u2013277.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"6562_CR265","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.trim.2007.05.005","volume":"18","author":"DG Lim","year":"2007","unstructured":"Lim DG, Joe IY, Park YH, et al. Effect of immunosuppressants on the expansion and function of naturally occurring regulatory T cells. Transpl Immunol. 2007;18:94\u2013100.","journal-title":"Transpl Immunol"},{"key":"6562_CR266","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1097\/TP.0b013e3182247b5f","volume":"92","author":"F Abadja","year":"2011","unstructured":"Abadja F, Atemkeng S, Alamartine E, Berthoux F, Mariat C. Impact of mycophenolic acid and tacrolimus on Th17-related immune response. Transplantation. 2011;92:396\u2013403.","journal-title":"Transplantation"},{"key":"6562_CR267","doi-asserted-by":"crossref","first-page":"3367","DOI":"10.1016\/j.transproceed.2009.08.031","volume":"41","author":"F Abadja","year":"2009","unstructured":"Abadja F, Videcoq C, Alamartine E, Berthoux F, Mariat C. Differential effect of cyclosporine and mycophenolic acid on the human regulatory T cells and TH-17 cells balance. Transplant Proc. 2009;41:3367\u20133370.","journal-title":"Transplant Proc"},{"key":"6562_CR268","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1517\/14740338.7.3.319","volume":"7","author":"AJ Czaja","year":"2008","unstructured":"Czaja AJ. Safety issues in the management of autoimmune hepatitis. Expert Opin Drug Saf. 2008;7:319\u2013333.","journal-title":"Expert Opin Drug Saf"},{"key":"6562_CR269","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1111\/apt.12042","volume":"36","author":"V Selvarajah","year":"2012","unstructured":"Selvarajah V, Montano-Loza AJ, Czaja AJ. Systematic review: managing suboptimal treatment responses in autoimmune hepatitis with conventional and nonstandard drugs. Aliment Pharmacol Ther. 2012;36:691\u2013707.","journal-title":"Aliment Pharmacol Ther"},{"key":"6562_CR270","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1002\/hep.21787","volume":"46","author":"AJ Montano-Loza","year":"2007","unstructured":"Montano-Loza AJ, Carpenter HA, Czaja AJ. Features associated with treatment failure in type 1 autoimmune hepatitis and predictive value of the model of end-stage liver disease. Hepatology. 2007;46:1138\u20131145.","journal-title":"Hepatology"},{"key":"6562_CR271","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1002\/hep.20235","volume":"39","author":"AJ Czaja","year":"2004","unstructured":"Czaja AJ, Carpenter HA. Progressive fibrosis during corticosteroid therapy of autoimmune hepatitis. Hepatology. 2004;39:1631\u20131638.","journal-title":"Hepatology"},{"key":"6562_CR272","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1053\/j.gastro.2011.02.065","volume":"140","author":"B Hoeroldt","year":"2011","unstructured":"Hoeroldt B, McFarlane E, Dube A, et al. Long-term outcomes of patients with autoimmune hepatitis managed at a nontransplant center. Gastroenterology. 2011;140:1980\u20131989.","journal-title":"Gastroenterology"},{"key":"6562_CR273","doi-asserted-by":"publisher","unstructured":"Vierling JM, Kerkar N, Czaja AJ, et al. Immunosuppressive treatment regimens in autoimmune hepatitis: systematic reviews and meta-analyses supporting AASLD guidelines. Hepatology. 2020. https:\/\/doi.org\/10.1002\/hep.31407.","DOI":"10.1002\/hep.31407"},{"key":"6562_CR274","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1038\/mt.2014.50","volume":"22","author":"S Ito","year":"2014","unstructured":"Ito S, Bollard CM, Carlsten M, et al. Ultra-low dose interleukin-2 promotes immune-modulating function of regulatory T cells and natural killer cells in healthy volunteers. Mol Ther. 2014;22:1388\u20131395.","journal-title":"Mol Ther"},{"key":"6562_CR275","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.jaut.2014.10.002","volume":"56","author":"CJ Bell","year":"2015","unstructured":"Bell CJ, Sun Y, Nowak UM, et al. Sustained in vivo signaling by long-lived IL-2 induces prolonged increases of regulatory T cells. J Autoimmun. 2015;56:66\u201380.","journal-title":"J Autoimmun"},{"key":"6562_CR276","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaut.2018.10.017","volume":"95","author":"LB Peterson","year":"2018","unstructured":"Peterson LB, Bell CJM, Howlett SK, et al. A long-lived IL-2 mutein that selectively activates and expands regulatory T cells as a therapy for autoimmune disease. J Autoimmun. 2018;95:1\u201314.","journal-title":"J Autoimmun"},{"key":"6562_CR277","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1081\/DDC-120025872","volume":"29","author":"E Kanaoka","year":"2003","unstructured":"Kanaoka E, Takahashi K, Yoshikawa T, et al. Continuous release of interleukin-2 from liposomal IL-2 (mixture of interleukin-2 and liposomes) after subcutaneous administration to mice. Drug Dev Ind Pharm. 2003;29:1149\u20131153.","journal-title":"Drug Dev Ind Pharm"},{"key":"6562_CR278","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.intimp.2019.03.064","volume":"72","author":"L Xu","year":"2019","unstructured":"Xu L, Song X, Su L, et al. New therapeutic strategies based on IL-2 to modulate Treg cells for autoimmune diseases. Int Immunopharmacol. 2019;72:322\u2013329.","journal-title":"Int Immunopharmacol"},{"key":"6562_CR279","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jhep.2004.03.008","volume":"41","author":"MS Longhi","year":"2004","unstructured":"Longhi MS, Ma Y, Bogdanos DP, et al. Impairment of CD4(+)CD25(+) regulatory T-cells in autoimmune liver disease. J Hepatol. 2004;41:31\u201337.","journal-title":"J Hepatol"},{"key":"6562_CR280","doi-asserted-by":"crossref","first-page":"4484","DOI":"10.4049\/jimmunol.176.7.4484","volume":"176","author":"MS Longhi","year":"2006","unstructured":"Longhi MS, Hussain MJ, Mitry RR, et al. Functional study of CD4+CD25+ regulatory T cells in health and autoimmune hepatitis. J Immunol. 2006;176:4484\u20134491.","journal-title":"J Immunol"}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-020-06562-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10620-020-06562-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-020-06562-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,6]],"date-time":"2023-10-06T05:43:53Z","timestamp":1696571033000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10620-020-06562-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,24]]},"references-count":280,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["6562"],"URL":"https:\/\/doi.org\/10.1007\/s10620-020-06562-2","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,24]]},"assertion":[{"value":"12 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Albert J. Czaja has no conflict of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}